



- (51) **International Patent Classification:**  
A61K 39/095 (2006.01) A61K 39/09 (2006.01)
- (21) **International Application Number:**  
PCT/EP2014/051670
- (22) **International Filing Date:**  
29 January 2014 (29.01.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
MI2013A000142 31 January 2013 (31.01.2013) IT
- (71) **Applicant:** BIOSYNTH S.R.L. [IT/IT]; Zona Industriale Loc.sentino, I-53040 Rapolano Terme (Siena) (IT).
- (72) **Inventor:** PORRO, Massimo; Zona Industriale Loc.sentino, I-53040 Rapolano Terme (Siena) (IT).
- (74) **Agents:** CALOGERO, Ida et al.; Studio Legale Bird & Bird, Via Borgogna, 8, I-20122 Milano (IT).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with information concerning incorporation by reference of missing parts and/or elements (Rule 20.6)

(54) **Title:** MULTIVALENT GLYCOCONJUGATE VACCINES

FIG.11



(57) **Abstract:** The present invention refers to conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S.pneumoniae, N.meningitidis, H.influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.

WO 2014/118201 A1

TITLE: MULTIVALENT GLYCOCONJUGATE VACCINES

-----

5

The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to *S.pneumoniae*, *N.meningitidis*, *H.influenzae*, *K. pneumoniae*, *M. tuberculosis*, *S.aureus*, or from intestinal infections due to *S. typhi*, *V. cholerae* and *E. coli*. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from *C. albicans* and *E. coli* systemic and genitourinary infections or for the protection from *M. bovis* infections in veterinary medicine.

Conjugate vaccines are the golden standard for measuring the nowadays success of clinical immunology. Since the early Ninety's, the advent of conjugate vaccines for prevention of *H.influenzae*, *N.meningitidis* and *S.pneumoniae* have dramatically improved the quality of life of the paediatric population in the western World. Such an outstanding success is now going to be extended to the countries of the developing world

thanks to the Immunization Expanded Program sponsored by WHO and the recently implemented national immunization programs through the Advance Market Commitment (AMC) of several countries.

5 For instance, vaccines like "Pevnar", present in the western markets since the year 2000 (formerly in its 7-valent formulation and now in its 13-valent formulation, both formulations containing single type-specific polysaccharide (Ps) of *S.pneumoniae* covalently

10 conjugated to the carrier protein CRM197) is nowadays recommended by WHO to all countries of the world for an unprecedented campaign of immunization for the protection of the paediatric population from the systemic infections due to *S.pneumoniae* (IPD or

15 Invasive Pneumococcal Diseases) which may ultimately induce acute bacterial meningitis. Indeed, this pathology is well documented as having a high mortality rate just because the time-interval of treatment is reduced to few hours from the beginning of the

20 symptoms, so that the rational strategy to follow is the prevention and not the therapy of the disease.

Because the amount of bacterial species significantly representative for the infections in humans by *S.pneumoniae* are many (up to 23 bacterial species out

25 of the more than 90 species today known) and the strategy of using single type-specific Ps conjugated to a protein carrier demands a significant dosage of the carrier protein when the vaccine formulation contains several conjugated antigens (e.g.: 13 or 15 or more if

including the most epidemiologically important serotypes indicated by WHO as being drug resistant, which include the bacterial serotypes (according to the Danish nomenclature) 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V,  
5 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) the possibility to reduce the amount of the carrier protein in the whole conjugate formulations is becoming a prioritary issue.

In fact, one must consider that a child undertaking  
10 immunization with the conjugate vaccines of *H.influenzae* (one type-specific conjugate of type b Ps), *N.meningitidis* (four group-specific conjugates of group A, C, W135 and Y Ps) and *S.pneumoniae* (up-to  
15 thirteen type-specific conjugates of type 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Ps) for the prevention of broad-spectrum IPD, is going to be injected with eighteen conjugated antigens which have the relevant burden of eighteen times the single, type-specific, dose of carrier protein. Furthermore, this  
20 dosage must be multiplied by three to four times, in consideration of the fact that three to four doses of the vaccines are necessary to confer full protection to the child in the first 2 years of age. All considered, the whole amount of carrier protein injected in a  
25 child, easily may reach doses of about 0.20 mg, at least in the case of the protein CRM197, with an obvious stress of the immune system which, however, so far seems to well tolerate such an amount of protein carrier for conferring helper T-cell dependency to the

host. However, by continuously up-grading the formulation of polyvalent vaccines like the one for prevention of *S.pneumoniae* infections, the amount of serotype Ps, ergo of carrier protein, is destined to  
5 climb over time.

In this regard, the author of the present invention has found a new category of conjugate antigens which feature the expression of multiple carbohydrate specificities, pre-determined and built-in the  
10 molecular construct, which uses one mole (or micromole or nanomole or picomole, all representative for a fraction of it) of protein carrier for carrying at least one mole (or micromole or nanomole or picomole, all representative for a fraction of it) of each of at  
15 least three different type (or group)-specific carbohydrate antigens, therefore a conjugate expressing at least a total of four different antigen-related serological specificities.

In this way, a vaccine formulation encompassing as many  
20 as eighteen type-specific conjugate antigens, as an example, will be synthesized by only using one third (or 33%) of the amount of carrier protein needed in the nowadays available single-antigen-associated formulation, so that the immunogenic burden on the  
25 immune-system of the host will be significantly lower and, consequently, safer.

It is in fact well known in immunology, the existence of the phenomenon defined as "carrier protein-dependent immune-suppression and immune interference " due to the

down-regulation of the immune system which becomes overwhelmed by the amount of protein antigen administered in repeated doses, for instance as a conjugate entity, especially when significant serological titers of pre-existing, carrier protein -  
5 specific, memory IgG antibodies, are present in the treated host (Dagan R. et al., Vaccine 28 (34): 5513-5523, 2010). The significant reduction of the protein carrier dosage by the present molecular model, however,  
10 warrants the full expression of helper T-dependency, according to the previous experimental work pointing out that the anamnestic IgG immune response of mammals towards a glycoconjugate antigen, is restricted to the hybrid linking area of the protein-  
15 carbohydrate epitopes with the specificity of the immune response confined to few monosaccharide residues of the covalently linked carbohydrate structure (Arndt and Porro, Immunobiology of Proteins and Peptides, Edited by M.Z. Atassi, Plenum Press, New York and  
20 London, Vol. 303, pages 129-148, 1991).

The above mentioned paper investigates on different chemical strategies and different MW of the Ps of *S.pneumoniae* conjugated to the carrier protein CRM197, for obtaining the optimal conjugate structure when  
25 using mono functionally-activated carbohydrate antigens; also, the paper investigates the most likely molecular area in the conjugate construct for being responsible of the helper-T dependency in mammals (through the analysis of the IgG isotype polyclonal

antibodies) by molecular mapping of the conjugates synthesized.

US 4,711,779 in the name of the same applicant discloses a molecular model of tri-valent glycoprotein  
5 expressing immunogenicity in mammals against a Gram-positive and a Gram-negative bacterium. The document referred to a molecular construct which used oligosaccharides of low MW, covalently coupled to the carrier protein via a linker derivative introduced at  
10 the end-reducing group discovered after chemical hydrolysis at low temperature; that conjugate featured a maximum of three different specificities (to the Protein CRM197, to Ps type 6A, to Ps group C); it used mono-functional oligosaccharides; the molecular  
15 construct induced serological specificity to the carrier protein and to each of the two carried carbohydrate structures.

US 5,306,492, also in the name of the same applicant, discloses oligosaccharide conjugate vaccines and an  
20 improved method for producing said oligosaccharide-based conjugate vaccines. The method involved the activation of the oligosaccharide haptens at high temperature and at the discovered end-reducing group before being covalently coupled to the carrier protein  
25 via a linker molecule; a typical conjugate expressed bivalent specificity (to the Protein CRM197 and to the type (or group)-Ps); it used mono-functional oligosaccharides; the molecular construct induced serological specificity to the carrier protein and to

the single-carried carbohydrate structure.

EP 1501542 in the name of the same applicant discloses a new method of producing HMW poly-disperse, cross-linked, polysaccharide-based conjugate antigens in high yield; a typical conjugate expressed specificity to the protein tetanus toxoid and to the carried type (or group)-Ps; it used poly-functional polysaccharides coupled to poly-functional protein carriers; the molecular construct induced serological specificity to the carrier protein and to the single-carried carbohydrate structure.

In addition, Porro M. et al. in *Medecine Tropicale*, 43: 129-132, 1983 first introduced the activation chemistry of a meningococcal group B oligosaccharide (previously hydrolyzed in controlled acidic conditions) at its end-reducing group, by ammonia and via reductive amination at low temperature (25-37°C); such mono-functional amino-group bearing oligosaccharide was then activated by the bis-succinimidyl ester of adipic acid and then conjugated to the amino groups of the Lysine residues of the carrier protein CRM197. The activated oligosaccharide antigen was mono-functional in the conjugation process and conjugation occurred without the previous activation of the carrier protein CRM197.

Moreover, Porro M. et al. in *Molecular Immunology*, 22: 907-919 (1985) first disclosed the activation chemistry of a pneumococcal type 6A oligosaccharide (previously hydrolyzed in controlled acidic conditions) at its end-reducing group, by ammonia and via reductive

amination in their paper titled "Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen". Such mono-functional amino-  
5 group bearing oligosaccharide was then activated by the bis-succinimidyl ester of adipic acid and then conjugated to the amino groups of the Lysine residues of the carrier protein CRM197. The activated oligosaccharide antigen was mono-functional in the  
10 conjugation process and without the previous activation of the carrier protein.

In a later paper in *Molecular Immunology*, 23: 385-391, (1986), the same authors featured a two-steps conjugation process to the same protein carrier CRM197,  
15 of two capsular oligosaccharides (derived from a Gram-negative and a Gram-positive bacterium, respectively) using the activation chemistry and the conjugation chemistry disclosed in the previous papers cited. Both the activated oligosaccharide antigens were mono-  
20 functional in the conjugation process and without the previous activation of the carrier protein.

It is observed that the conjugate disclosed in such paper involves different end-point activated low MW capsular oligosaccharides (namely Ps of *Streptococcus pneumoniae* type 6A and Ps group C of *Neisseria meningitidis*). The use of such end-point activation provides low coupling yields therefore resulting in a  
25 disproportioned, huge, amount of carrier protein with

respect to the maximum amount of the two carried oligosaccharide structures (around 31.2 µg of CRM197 with 4.8 µg of Ps 6A and 3 µg of Ps type C, see page 387, left column of the above referred 1986 paper).

5 Finally, in a later paper (Porro M. Edited by R. Bell and G. Torrigiani (World Health Organization), pages 279-306; John Wiley & Sons Publishers, New York 1987, the author of the present invention summarizes the concepts and the technical procedures above referenced

10 for conjugate antigens composed of protein carrier and a maximum of two different carbohydrate structures. In developing the above state of the art, the preferred (not limitative) embodiment of the basic molecular construct subject of the present invention is composed

15 by a multivalent, preferably a tetra-valent semi-synthetic glycoprotein which features built-in multiple epitopes and expresses its helper T-dependent immunogenic specificity "in vivo" to the protein CRM197, as well as to three carried type-specific Ps,

20 for example Ps of *S.pneumoniae*. As an example, any triad of the Ps type 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F of *S.pneumoniae* such as the triad consisting of the Ps type 3,6A,7F may be conjugated to

25 the carrier protein. As an example, the term tetra-valent is referred the carrier protein antigen (acting per se as an antigen and not merely as a carrier) plus the three carried Ps antigens.

Thus, the novel new molecular construct induces serological specificity to the carrier protein and to each of the three carried carbohydrate structures.

This semi-synthetic tetravalent antigen can be considered as the novel new precursor of a new generation of conjugate antigens expressing multiple specificities for obtaining vaccines with an always broader spectrum of protection against a variety of bacterial pathogens while drastically reducing the amount of carrier protein, in order to obtain a rational improvement on:

- A) the cost of production of the vaccines;
- B) their production efficiency in terms of improvement of coupling yield that allowed the synthesis of the glycoprotein with three (or more) Ps antigens (also featuring high MW);
- C) their production accuracy in terms of quantitative determination from the serological point of view of the amount of covalently bound Ps by using the specific inhibition-ELISA assay reported in the present application, for an accurate quantification of the multiple carbohydrate antigens present in the disclosed molecular construct, on the basis of immunochemical, rather than chemical quantification of the cited prior art (see Porro et al. 1986), especially in the various cases where highly significant similarities exist among specie-specific carbohydrate structures;
- D) their safety as related to the lower amount of the protein dosage impacting on the immune system of the

target population. In fact, said protein dosage is ca.30% (around 10 µg of protein in the dose involving a whole 15-valent formulation at 2 ug protein/triad/dose) of the protein dose present in the conjugate of CRM197 with the two Ps of the paper Porro et al., 1986. Such reduction would not be predictable for the skilled person in such amount based on the available stoichiometry reported in the paper where an immunizing dose would contain at least 31.2 µg of CRM197; therefore, for a multivalent composition comprising 13 or 15 conjugated antigens, even assuming the possibility of preparing, according to the previous chemistry, the multiple tetravalent molecular model detailed of the invention, the amount of protein CRM197 in the formulation would be  $31.2 \times 15/3 = 156.0 \mu\text{g}$  vs.10 µg of the multivalent conjugate of the invention; and, consequently:

E) the public utility of such conjugate vaccines.

The present invention opens new avenues in the field of clinical immunology and vaccinology. In fact, the built-in multiple antigenicity of the disclosed molecular construct, specific for different bacterial antigens, actually parallels, in the innovative field of poly-pharmacology, the synthesis of a drug designed a priori for simultaneously reaching multiple receptors of pharmacological relevance, so allowing the reduction of the number of drugs to be administered in associated form (Besnard J. et al., Nature, 492: 215-220, 2012). Therefore, it is an object of the present invention an

antigenic multivalent molecular construct consisting of a basic unit comprising a helper-T dependent carrier protein covalently bound to a minimum of three carbohydrate structures of different serological  
5 specificity, wherein each carbohydrate structure comprises at least one of the repeating basic antigenic epitope consisting of a minimum of five to twelve monosaccharide residues, preferably a minimum of eight to twelve monosaccharide residues, as assessed by  
10 molecular mass determination and NMR spectroscopy (equivalent to different numbers of Basic Repeating Units depending from homologous or heterologous sequences), said repeating basic antigenic epitopes being assessed by reactivity with type-  
15 specific or group-specific polyclonal or monoclonal antibodies through the determination of their respective MIC<sub>50</sub> values in the inhibition of their homologous Polysaccharide-Antibody reference system. According to the present invention, the term  
20 carbohydrate structures is intended to comprise oligosaccharides (natural or synthetic) or polysaccharides (such as capsular polysaccharides).  
The T-helper dependent carrier protein of the antigenic multivalent molecular construct according to the  
25 invention is covalently bound to a minimum of three (for example three or four or five) carbohydrate structures of different serological specificity up to the limit of reactivity of the nucleophilic amino groups of the structural amino acids, mainly Lys but

also, for example, of the basic features of Arg and Hys, present in the carrier protein structure involved in the coupling reaction.

According to preferred embodiments of the present invention the helper-T dependent carrier protein covalently bound to a minimum of three different carbohydrate structures of different serological specificity, is selected between the group of natural diphtheria mutant protein CRM197 (PRF 1007216A),  
5 diphtheria toxoid (CAE11230.1 of the homologous toxin), tetanus toxoid (ID No. AAK72964.2 of the homologous toxin), Protein D from *Haemophilus influenzae* (AAA24998.1); pneumococcal surface proteins (PspA EMBL CBW33751.1 and PspC EMBL  
15 ACF56456.1); pneumococcal toxin (*Pneumolysin* EMBL ACF56060.1) or variants and derivatives thereof. Particularly, when the tetanus toxoid is employed it is preferred to employ a chemically derivatized toxoid by adipic acid dihydrazide spacer (tetanus toxoid-ADH).

20 According to the most preferred embodiment of the present invention the carrier protein is the natural diphtheria mutant protein CRM197.

Such protein was first reported by Uchida and Pappenheimer in the mid of the seventy's (Uchida T. et al., J. Biol. Chem. 248, 3838-3844, 1973) and its  
25 possible use as novel immunogen against diphtheria toxin, as being in immunogenic correlation with diphtheria toxoid, was already reported by the applicant (Porro M. et al., J. Infect. Dis., 142 (5),

716-724, 1980). Since then, the applicant used CRM197 as ideal helper-T dependent carrier protein for carbohydrate antigens, once it became understood the reasons for the peculiar immunogenic characteristics of the latter group of antigens in human subjects, in the specific age involving the maturation of the immune system (from ca. 2 months to around 2 years of age). The protein CRM197 is composed by a sequence of 535 amino acids, just like diphtheria toxin (Giannini G. et al., Nucl. Acid Res., 12, 4063-4069, 1984) but shows a point-mutation at the amino acid in position 52, where Glu replaces Gly. Its antigenicity has been reported as mainly directed to four areas of the sequence, when using monoclonal antibodies, namely the AA sequences 1-156, 157-193, 293-345 and 465-535 (Zucker D. and Murphy J.R., Mol. Immunol. 21, 785-793, 1984). The protein also features 39 Lys residues and one amino terminal group, for a total of reactive 40 amino groups, which are purposely used for the chemical reactions involved in the various conjugation strategies.

The carrier protein CRM197 of the conjugate of the invention is usually prepared using the clones of *C. diphtheriae* C7( $\beta$ 197)<sup>tox-</sup> but it may also be obtained by clones of *P. fluorescens*, among others.

According to preferred embodiments of the antigenic multivalent molecular construct of the invention the carried carbohydrate structures are selected among, but not limited to, Ps of *Streptococcus pneumoniae* (type

1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9N, 9V, 10A, 11A, 11B, 11C, 11F, 12F, 14, 15A, 15B, 15C, 17F, 18C, 19A, 19F, 20, 22F, 23A, 23F, 33F, 35B, among Ps of *Neisseria meningitidis* (group A, C, W135 and Y), *Haemophilus*  
5 *influenzae* (type b), *Mycobacterium tuberculosis* and *Klebsiella pneumoniae* (i.e. K1-K20 antigens), *Salmonella typhi* (type Vi), *Escherichia Coli* (type K1), *Vibrio cholerae* or a combination thereof. Preferably, such combination of Ps is carried out among Ps belonging to  
10 one or more infectious agent causing systemic and pulmonary diseases (*Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenza*, *Mycobacterium tuberculosis*, *Staphylococcus aureus* and *Klebsiella pneumoniae*) in addition to Ps belonging to one or more  
15 infectious agents causing intestinal diseases (*Salmonella typhi* (type Vi), *Escherichia Coli* (type K1), *Vibrio cholerae*) or Ps belonging to other infectious agents like *Candida albicans* causing systemic and genitourinary infections.

20 Based on the above embodiments, it is also possible to prepare hybrid molecular constructs where the carrier protein works as helper T-dependent vector for antigens of *S.pneumoniae* and *N.meningitidis* and other antigens simultaneously. These hybrid molecular constructs do  
25 not exist in nature as the antigenic surface of Gram-negative and Gram-positive bacteria differ significantly between them in terms of molecular architecture of the bacterial cell and the biologic mechanisms through which they induce protective

immunity in mammalian hosts. For instance, while protective immunity induced against the capsular Ps of the Gram-negative bacterium *N.meningitidis* involves complement-dependent bactericidal activity, that  
5 induced by the Gram-positive bacterium *S.pneumoniae* involves opsono-phagocytic activity, yet complement-dependent. In the case of such a hybrid category of synthetic antigens both pathways are specifically induced (Porro M. et al., *Molecular Immunol.*, 23: 385-  
10 391 (1986), a fundamental difference shown from the properties of each single natural antigens.

The present invention contemplates also the association of the antigenic multivalent molecular construct according to the invention with the class of LPS-based  
15 vaccines defined as Endotoxoids. Endotoxoids are non-toxic complexes of LPS with SAEP (Synthetic Anti Endotoxin Peptides) which have been shown to be useful in administering LPS as immunogen to mammals (Rustici A. et al., *Science*, 259:361-365, 1993).

20 Such association may contemplate the separate, simultaneous or sequential use or administration of the antigenic multivalent molecular construct and the Endotoxoid(s) of gram negative bacteria. The Endotoxoid may be selected among Endotoxoid B (*N. meningitidis* Group B), Endotoxoid of *E. coli*, *S. typhi*, *V. cholerae*,  
25 *S. enteritidis*, *B. pertussis*.

Hybrid molecules according to the described molecular construct may also include the capsular polysaccharide of *Mycobacterium tuberculosis*, a pathogen which is

continuously expanding throughout the world and for which a "sterilizing" vaccine, that is a vaccine which is protective in the bloodstream and in the lungs of the host, still does not exist. The polysaccharide capsule of *M.tuberculosis* predominantly consists of an  $\alpha$ -D-(1→4)-glucan polymer with  $\alpha$ -(1→6) branches which displays structural similarities with cytosolic glycogen. Mycobacterial  $\alpha$ -glucan has an apparent molecular mass of  $1.3 \times 10^7$  and is expressed both *in vitro* and *in vivo* (Schwebach, J. R., et al. 2002. Infect. Immun.70:2566-2575); also, accompanying antigens like the glycolipids LAM (Lipoarabinomannan) and PIM (phosphatidylinositol mannoside) are possibly associated with the polysaccharide capsule. One or all of these carbohydrate antigens present in the capsular layer may then be conjugated to a carrier protein like CRM197, as an example, and to become part of the molecular construct of the invention.

It is also possible to foresee an antigenic multivalent molecular construct wherein the carried carbohydrate structures are those belonging to *Mycobacterium bovis* for the prevention of the infection affecting, other than humans, cattle, pigs, domestic cats, equids or sheep cattle.

Another case where the multivalent molecular construct of the invention can be applied with substantial advantages in terms of having a rational formulation design for a new vaccine, is that related to the pathogenic features of the fungus *Candida albicans*. The

commensal fungus *Candida albicans* causes mucosal candidiasis in immunocompromised patients, which includes oropharyngeal, esophageal, gastrointestinal, and vaginal infections. Vulvovaginal candidiasis (VVC) and antimycotic-refractory recurrent VVC is also a frequent problem in healthy childbearing women. Both these mucosal infections can affect the quality of life and finding a new vaccine against candidal infections would be a new important tool to prevent mucosal candidiasis and would be of benefit to many patients. An effective systemic and local vaccine still does not exist in the prevention of such chronic, recurrent, infections. The antigenic repertoire of *C. albicans* contains, among others, several antigens of glucidic nature, namely the 1,3- $\beta$ -glucan (Bromuro et al., 2010), and the L-mannans as  $\beta$ -1,2-mannotriose (Han et al., 2010; Xin et al., 2008). Such structurally different carbohydrate antigens can be all conjugated to a carrier protein of choice for preparing a multivalent entity like the one here disclosed, which to some extent can mimic the whole, carbohydrate-based, antigenic structure of the pathogen, which, in the case of genitourinary infections, may be also rationally associated with *E. coli* carbohydrate-based antigens in conjugated form. Furthermore, another case where the multivalent molecular construct of the invention can be applied with substantial advantages in terms of having a rational formulation design for a new vaccine, is that

related to the pathogenic features of *Staphylococcus aureus*. This pathogen, as reported by O’Riordan and Lee Clin. Microbiol. Rev., 17:218-234, 2004 and below synthesized, is an opportunistic bacterial pathogen responsible for a diverse spectrum of human and animal diseases. *Staphylococcus* is also a major cause of wound infections and has the invasive potential to induce osteomyelitis, endocarditis, and bacteremia, leading to secondary infections in any of the major organ systems.

5 Staphylococcal infections occur most frequently when the skin or mucosal barriers are breached, following insertion of a foreign body, and in hosts with compromised immune systems. Because of the prevalence of antibiotic-resistant strains and the recent

10 emergence of clinical isolates resistant to vancomycin, control of *S. aureus* has become increasingly difficult. *Staphylococcus* plays a major role in nosocomial infections and recently has been acknowledged as an important cause of community-acquired infections.

15 Community acquired *S. aureus* infections often occur in otherwise healthy individuals who lack the expected risk factors for *S. aureus* infections, e.g., recent hospitalization or surgery, residence in a long-term-care facility, or use of injected drugs. Among other

20 antigens, the bacterial component that mainly affect the pathogenesis of *S. aureus* infections include a capsular polysaccharide, which allows staphylococci to adhere to eukaryotic membranes, resist opsonophagocytosis, lyse eukaryotic cells, and trigger

25

the production of a cascade of host immunomodulating molecules. Capsules from at least 18 *S. aureus* strains have been described and at least four of them characterized. Each contains hexosaminuronic acids.

5 Biochemical characterizations have been performed on some polysaccharides purified. Strain M expresses a type 1 capsule with the following structure:  $(\rightarrow 4)\text{-}\alpha\text{-d-GalNAcA-(1}\rightarrow 4)\text{-}\alpha\text{-d-GalNAcA-(1}\rightarrow 3)\text{-}\alpha\text{-d-FucNAc-(1}\rightarrow)_n$ ; a taurine residue is amide linked to every fourth d-

10 GalNAcA residue. Two other strains, D and SA1 mucoid, produce capsules that are serologically and biochemically similar to that produced by strain M. The capsule of serotype 2 has the structure:  $(\rightarrow 4)\text{-}\beta\text{-d-GlcNAcA-(1}\rightarrow 4)\text{-}\beta\text{-d-GlcNAcA-(1-alanyl)-(1}\rightarrow)_n$ . Type 5 and 8 capsular polysaccharides (CP5 and CP8, respectively)

15 are structurally very similar to each other and to the capsule made by strain T. Type 5 has the structure  $(\rightarrow 4)\text{-}3\text{-O-Ac-}\beta\text{-d-ManNAcA-(1}\rightarrow 4)\text{-}\alpha\text{-l-FucNAc-(1}\rightarrow 3)\text{-}\beta\text{-d-FucNAc-(1}\rightarrow)_n$ , and type 8 has the structure  $(\rightarrow 3)\text{-}4\text{-O-Ac-}\beta\text{-d-ManNAcA-(1}\rightarrow 3)\text{-}\alpha\text{-l-FucNAc-(1}\rightarrow 3)\text{-}\beta\text{-d-FucNAc-(1}\rightarrow)_n$ .

20 Type 5 and 8 polysaccharides differ only in the linkages between the sugars and in the sites of O-acetylation of the mannosaminuronic acid residues, yet they are serologically distinct.


25 Very recently (Nanra et al., Human Vaccines and Immunotherapeutics, 9:3, 480-487, 2013) has been reported the role of the capsular Ps of *S. aureus* in preventing the non-specific OPA (opsonophagocytosis) killing in the presence of variable amount of

complement but in the absence of specific antibodies to Ps ; in contrast, when in the presence of specific antibodies to Ps raised in *rhesus* macaques by CRM197-Ps conjugates of type 5 and 8, OPA killing was very  
5 efficient on *S. aureus*, underlining the fundamental role of the antibodies to the Ps capsule for eliciting the immunological defenses to this pathogen when in capsulated form.

Accordingly, it is also the subject of the present  
10 application the innovative formulation of a vaccine against *S. aureus*, composed of a molecular construct in the form of glycoconjugate carrying at least three different type-specific Ps antigens of *S. aureus* on the carrier protein of choice, most preferably CRM197.

15 According to one preferred embodiment the carried carbohydrate structures of *S.pneumoniae* antigens selected according to a specific embodiment of the invention are the polysaccharide type 3, 6A, 7F.

The polysaccharide type 3 responds to the following  
20 structure (Reeves R.E. and Goebels W.F., J. Biol. Chem., 139: 511-519, 1941):

***S. Pneumoniae Type 3***

$\rightarrow 4$ - $\beta$ -D-Glcp-(1 $\rightarrow$ 3)- $\beta$ -D-GlcpA-(1-



Reactive groups:

\*2,3-hydroxyls

The structure features one pair of -OH groups/Base Repeating Unit (BRU) which means there is a possibility to activate it at various degrees using the method disclosed by the Applicant in the above mentioned Patent EP 1501542.

The polysaccharide type 6A responds to the following structure (Rebers P.A. and Heidelberger M., J. Am. Chem. Soc., 83: 3056-3059, 1961):

***S. Pneumoniae Type 6A***



**Reactive groups:**  
**\*3,4 Hydroxyls**

The structure features one pair of -OH groups/Base Repeating Unit (BRU) which means there is a large possibility to activate it at various degrees using the method disclosed by the applicant in EP 1501542.

The polysaccharide type 7F responds to the following structure (Moreau M. et al., Carbohydrate Res., 182(1):79-99, 1988):



the following triads of Ps: CRM197-3,6A,7F; CRM197-5,9V,19F; CRM197-1,14,19A; CRM197-22F,23F,33F; CRM197-4,6B,18C.

The antigenic multivalent molecular construct of the invention may be either in monomeric or polymeric form. The invention is also directed to one or more than one antigenic multivalent molecular construct as above defined in a vaccine for the protection of a subject (preferably belonging to the human paediatric population) from the infections due to at least one agent selected among *S.pneumoniae*, *N.meningitidis*, *H.influenzae*, *K. pneumoniae*, *M.tuberculosis*, *S. typhi*, *S. aureus* and *E. coli*. Preferably, the combination of the antigenic multivalent molecular construct of the invention will be carried out by selecting antigenic multivalent molecular construct carrying Ps belonging to one or more infectious agent causing systemic and pulmonary diseases (such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Mycobacterium tuberculosis*, *Staphylococcus aureus* and *Klebsiella pneumoniae*) in addition to Ps belonging to one or more infectious agent causing intestinal diseases (*Salmonella typhi* (type Vi), *Escherichia Coli* (type K1, *V. cholerae*) or Ps originating from other infectious agents like the commensal fungus *Candida albicans* causing genitourinary infections also in association with the pathogen *E. coli*.

It is in fact possible to foresee a vaccine against *Candida albicans* and *Escherichia coli* infections (preferably for the immunization of the female population) comprising one or more antigenic multivalent molecular construct wherein the carried

carbohydrate structures are those belonging to *Candida albicans* and *Escherichia coli*.

Another aspect of the present invention contemplates a vaccine against *Mycobacterium bovis* infections for the immunization of cattle, pigs, domestic cats, equids or sheepcattle.

Furthermore, the invention features a vaccine formulation comprising one or more molecular constructs of different antigenic specificities according to the present invention, in a physiologically acceptable vehicle, optionally together with an adjuvant and/or excipients pharmaceutically acceptable.

The invention is further directed to a broad-spectrum polyvalent vaccine formulation as above defined, for use in human medical field for the protection of a subject from the infections due to at least one agent selected among *S.pneumoniae*, *N.meningitidis*, *H.influenzae*, *K. pneumoniae*, *S. aureus*, *M.tuberculosis*, *S. typhi*, *E. coli*, *V. cholerae* and *C. albicans*. Preferably, said subject belongs to the paediatric population.

In addition, the molecular model disclosed in the present application is the base for a broad-spectrum polyvalent vaccine for the prevention of type-specific *S.pneumoniae* bacterial infections containing from a minimum of 7 types (for example 9, 12, 15, 18, 21, 24) and up-to 25 different carbohydrate structures of type 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18 C, 19A, 19F, 20, 22F, 23F, 33F.

It is also possible to foresee a vaccine contemplating the combination of one or more tetravalent antigenic molecular construct (carrying three Ps) of the

invention with one bivalent or trivalent antigenic construct (carrying one or two Ps) or alternatively with one pentavalent antigenic construct (carrying four Ps), when the final number of carbohydrate structures  
5 that the skilled person intends to achieve is different from a multiple of three.

When considering the basic conjugate carrying three moles (or fractions of it) of structurally different carbohydrate antigens per mole (or fractions of it) of  
10 carrier protein, the amount of carrier protein can be reduced to ca. 30% of that present in any of the today available pneumococcal conjugate formulations for the paediatric population (e.g.: *Prevnar* which is the object of the patent EP1868645, and *Synflorix*).

15 A practical example of broad-spectrum (e.g.:18-valent) formulation of a vaccine for the prevention of IPD (Invasive Pneumococcal Disease) due to *S.pneumoniae*, which is based on the antigenic multivalent molecular construct disclosed in this application, is the  
20 association of at least three, four, five or preferably all the following multivalent conjugates, where the protein CRM197 (or any other immunogenic protein) serves as helper T-dependent carrier:

CRM197-3,6A,7F; CRM197-4,5,9V; CRM197-1,6B,14; CRM197-  
25 18C,19A,23F; CRM197-6C,19F,22F; CRM197-12F,15B,33F.

In such an example, just six multivalent conjugates cover the broad-spectrum of serotypes selected.

In sharp contrast, nowadays available formulations would require the association of eighteen conjugates.

30 It goes without saying that any combination (triad or quartet) of the Ps type 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F,

20, 22F, 23F, 33F of *S. pneumoniae* may be contemplated. Another preferred example of broad-spectrum (e.g.: 15-valent) formulation of a vaccine for the prevention of IPD (Invasive Pneumococcal Disease) due to  
5 *S.pneumoniae*, comprises multivalent conjugates of the invention contemplating the following triads of Ps: CRM197-3, 6A, 7F; CRM197-5, 9V, 19F; CRM197-1, 14, 19A; CRM197-22F, 23F, 33F; CRM197-4, 6B, 18C.

The injected amount of protein carrier in the former  
10 formulation is therefore ca. 30% (on weight basis) of the amount of carrier protein present in the latter formulation, with a highly significant reduction of at least 70% of it (on weight basis).

To make a comparison, the total amount of carrier  
15 protein today present in the 13-valent "Pprevnar" vaccine (formulation composed of 13-associated monovalent antigens, object of the patent EP 1868645) is ca.32 µg, at the clinical dose of ca. 2 µg Protein/ca. 2 µg of each Ps antigen conjugated, for a  
20 total of 31 µg of Ps antigens [average ratio (R) Protein/Ps (w/w) = 1.03]; at about the same ratio Protein/type-specific Ps (as shown by the above disclosed multivalent conjugate CRM197-3, 6A, 7F), the total amount of carrier protein in the exemplified 18-  
25 valent formulation is just 12 µg or the 37.5% of that present in the 13-valent formulation of "Pprevnar" (data on the composition of the "Pprevnar" vaccine and "Synflorix" vaccine are from the publically available documents released from US-FDA and EMA).  
30 Additional examples of vaccine formulations are based on the antigenic multivalent molecular construct according to the invention for the prevention of group-

specific *N.meningitidis* bacterial infections (group A,C,W135,Y).

The same strategy relative to the conjugation process and controls above disclosed for the multivalent  
5 antigenic molecular construct of *S.pneumoniae* type 3,6A and 7F, can be used for other carbohydrate structures like those of *N.meningitidis*.

In this case, just one multivalent antigen containing the group-specific carbohydrate structures  
10 (polysaccharide A, C,W135 and Y) may constitute the formulation of the vaccine.

Therefore it is another object of the invention a broad spectrum vaccine formulation for the prevention of the infection due to *Neisseria meningitidis* comprising an  
15 antigenic multivalent molecular construct containing the group-specific carbohydrate structures A, C, W135 and Y.

According to a preferred embodiment the present invention is directed to a broad spectrum vaccine  
20 formulation for the prevention of the pulmonary infection (preferably in pediatric population) due to more than one infectious agent selected among *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Staphylococcus aureus*,  
25 *Klebsiella pneumoniae*, *M. tuberculosis*, comprising more than one antigenic multivalent molecular construct containing said agent-specific carbohydrate structures. Alternatively, the present invention relates to a broad spectrum vaccine formulation for the prevention of the  
30 intestinal infections (in the pediatric or adult human population) due to more than one infectious agent

selected between *Salmonella typhi*, *Escherichia coli* and *Vibrio cholera*.

Another embodiment foresees a broad spectrum vaccine formulation for the prevention of the systemic or genitourinary infections due to pathogens like the commensal fungus *C. albicans* and *Escherichia coli*, said vaccine comprising more than one antigenic multivalent molecular construct containing said agent-specific carbohydrate structures.

According to a particular embodiment of the present invention the aforementioned vaccine formulations may be administered separately, simultaneously or sequentially with an Endotoxoid antigen of gram negative bacteria, said Endotoxoid being selected in the group consisting of Endotoxoid of *N. meningitidis* Group B, *E. coli*, *S. typhi*, *V. cholerae*, *S. enteritidis*, *B. pertussis*.

When considering the basic conjugate construct carrying the four structurally different carbohydrate antigens, the amount of carrier protein can be reduced to at least 25% of that present in any of the today available associated conjugate formulations (e.g.: "Menactra" and "Menveo") according to the public available documents on their composition and formulation (a total of 48 and 47 µg/dose of Diphtheria Toxoid and CRM197, respectively) released from US-FDA and EMA.

The immunogenic dose of polyvalent formulations of the molecular construct disclosed in this application is referred to the dose of each carbohydrate structure carried. In this respect, the dose may range between 0.1 to 10 µg, preferably 1 µg, of each conjugated

carbohydrate antigen in infants and children. Those that are expert in the clinical field will help finding the optimal dose in the target population.

Preferably, said vaccine formulations further comprises

5 a mineral or a chemically synthetic or a biological adjuvant. Mineral or chemically synthetic or biological adjuvants can be used with the molecular construct disclosed in this application, in order to benefit from any immunological boost that can be effective in

10 lowering the optimal immunogenic dose in humans so to further reduce the total amount of carrier protein. Particularly, preferred inorganic adjuvants in the vaccine formulations according to the invention for use in human beings are selected between Aluminium

15 Phosphate ( $AlPO_4$ ) and Aluminium Hydroxide; preferred organic adjuvants are selected from squalene-based adjuvants such as MF59, QF 21, Addavax; preferred bacterial antigens are selected between Monophosphoryl-lipid A, Trehalose dicorynomycolate (Ribi's adjuvant).

20 In vaccine formulations for use in the veterinary field Freund's adjuvant (complete or incomplete) is preferred. The dose of adjuvant may range between 0.1-1 mg/dose, preferably being 0.5 mg/dose.

More preferably, such formulation is suitable for the

25 administration by subcutaneous or intramuscular or intradermal or transcutaneous route. Conveniently, such administration may be carried out by conventional syringe injection or needle-free tools.

The vaccine formulations according to the invention may

30 be administered according to a protocol which requires single or multiple administrations, according to the physician, pediatrician or veterinary instructions.

The present invention is further directed to a conjugation process for preparing the antigenic multivalent molecular construct which employs the chemistry disclosed in the patent EP 1501542, where  
5 each of the at least three carbohydrate structures is chemically activated to mono-functionality or polyfunctionality by O-de-hydrogen uncoupling via oxidation and reductive amination forming imine reduced bonds with an alkyl diamine spacer, then derivatized to  
10 active esters, such ester-derivative carbohydrate structures being finally and simultaneously coupled or step-by-step coupled to the amino groups of the polyfunctional carrier protein through the formation of amide bonds.

15 Preferably, said carbohydrate structures are chemically activated in their corresponding diamine butyric acid derivatives and the active esters are succinimidyl esters.

As an example, the chemical activation of the triad of  
20 polysaccharide type 3, 6A, 7F (or of the other preferred triad 4,5,9V; 1,6B,14; 18C,19A,23F; 6C,19F,22F; 12F,15B,33F; 5,9V,19F; 1,14,19A; 22F,23F,33F; 4,6B,18C) of *S.pneumoniae* to the homologous Ps-DAB (diamine butyric acid derivative) has  
25 been performed according to the process disclosed by the Applicant in Claim 1 of EP 1501542, and the polyfunctional carrier protein was CRM197.

Alternatively, the conjugation process for preparing the antigenic multivalent molecular construct employs  
30 the chemistry disclosed in Claim 8 of EP 1501542 involving simultaneous coupling or step-by-step coupling of the amino groups of the poly-functional

carrier protein with the at least three different carbohydrate structures, via reductive amination forming imine-reduced bond, such carbohydrate structures being previously activated to  
5 monofunctionality or polyfunctionality, with or without spacers, by O-de-hydrogen uncoupling via oxidation. As it can be inferred, the above disclosed molecular model can be further developed to contain more than three (for example four or five) different carbohydrate  
10 structures per single mole (or fractions of it) of protein carrier, this possibility depending from three main parameters of the molecular construct:

- a) the physical-chemical features of the carrier protein, which structure should feature the highest  
15 possible amount of Lysine residues (source of reactive -NH<sub>2</sub> groups);
- b) the "ad hoc" selected polydisperse MW of the different carbohydrate structures featuring an optimal activation rate while limiting the negative effects of  
20 steric hindrance phenomena in the coupling reaction, and
- c) the efficiency of the chemistry used for the activation of the different carbohydrate structures and for the synthesis of the molecular construct (the  
25 preferred chemistry for a high efficiency in the optimal activation of carbohydrate structures is the O-de-hydrogen uncoupling via oxidation, with or without spacer, while that for a high efficiency in the conjugation reaction is through amide bond formation  
30 via active esters between the carbohydrate structures and the carrier protein; also preferred for the

conjugation reaction, is the chemistry which uses the formation of an imine reduced bond between the O-dehydrogen uncoupling oxidized carbohydrate structures, with or without spacers, and the carrier protein, via  
5 direct reductive amination).

The process of conjugation employed according to the invention foresees the multi-step activation of the (at least three) polysaccharides (that consequently may have indifferently, although homogeneously, either low  
10 or high MW) in order to improve the coupling yields with the carrier protein. This is different from the conjugation process of the prior art (see Porro et al. Molecular Immunology, Vol. 23, pages 385-391, 1986) involving the end-point activation at low temperature  
15 of the low MW Ps employed which, consequently, resulted in a low coupling yield while not involving the molecular cross-linking of the conjugate.

Another difference with the previous model lies in the stoichiometric features of that previous construct (w/w  
20 ratio Protein/Ps) as well as in the determination of the Ps employed which is carried out by immunochemistry in the present invention vs the chemistry approach used in the prior art. This has allowed the possibility in the present invention to determine the quantitative  
25 amount of Ps having very similar structures when present in the same molecular construct.

Finally, the present invention is directed to the antigenic multivalent molecular constructs which are obtainable through the conjugation processes above  
30 disclosed.

The present invention will be further illustrated according to preferred embodiments with particular

reference to the enclosed figures, wherein:

- Figure 1 shows a comparison between  $^1\text{H-NMR}$  spectrum of native Ps 3 (grey) and activated Ps 3-DAB 50% Ox (black) of Ps 3 and Ps3-DAB derivative.
- 5 - Figure 2 shows  $^1\text{H-NMR}$  spectra of Ps 3-DAB 50% Ox, with diffusion filters. Spectrum in black 60% GRAD, spectrum in gray 2% GRAD assessing absence of free DAB in the derivative.
- Figure 3 shows Ps 3-DAB derivative, 50% Ox,  $^1\text{H-NMR}$  spectrum and quantization of DAB activation (2% on molar basis).
- 10 - Figure 4 shows a comparison between the  $^1\text{H-NMR}$  spectrum of native Ps6A (grey) and activated Ps6A-DAB derivative 50% Ox (black).
- 15 - Figure 5 shows  $^1\text{H-NMR}$  spectra of Ps 6A-DAB 50% Ox, with diffusion filters. Spectrum in black 60% GRAD, spectrum in gray 2% GRAD assessing absence of free DAB in the derivative.
- Figure 6 shows Ps 6A-DAB derivative, 50% Ox,  $^1\text{H-NMR}$  spectrum and quantization of DAB activation (2.3 % on molar basis).
- 20 - Figure 7 shows a comparison between the  $^1\text{H-NMR}$  spectrum of native Ps7F (grey) and activated Ps7F-DAB derivative 10% Ox (black). The signal at 1.92 ppm, only present in the native Ps, is due to free acetate ion. OAc signal at 2.24 ppm remains the same after DAB activation.
- 25 - Figure 8 shows  $^1\text{H-NMR}$  spectra of Ps 7F-DAB 10% Ox, with diffusion filters. Spectrum in black 60% GRAD, spectrum in gray 2% GRAD assessing absence of free DAB in the derivative.
- 30

- 5 - Figure 9: shows Ps 7F-DAB derivative 10% Ox, <sup>1</sup>H-NMR spectrum and quantization of DAB activation (1.7 % on molar basis). Arrow indicates the reference signal at 5.65 ppm ( $\alpha$ -proton of glucose or galactose) for quantization of the DAB activation.
- Figure 10 shows GPC analysis of the antigenic multivalent molecular construct CRM197-3,6A,7F.
- 10 - Figure 11 shows the GPC analysis of the four components just mixed together (CRM197 + Ps 3-DAB + Ps 6A-DAB + Ps 7F-DAB) in order to show absence of any significant amount of complex formation among the single antigens.
- 15 - Figure 12 shows SEC-HPLC analysis of the multivalent antigen, following purification on Sepharose 4B-CL, with specific reference to the profile of the carrier protein CRM197.
- Figure 13 shows SEC-HPLC analysis of CRM197 as native protein, when mixed with Ps 3-DAB , Ps 6A-DAB and Ps 7F-DAB.
- 20 - Figure 14 shows the SDS-PAGE analysis (9 % Glycine buffer) showing the pattern of the purified multivalent antigen CRM197-3,6A,7F. Legend of the loaded samples:1: CRM197 as reference; 2: Polydispersed MW of the purified multivalent conjugate antigen CRM197-3,6A,7F; 3: Mixture of CRM197+Ps3-DAB+Ps6A-DAB+Ps7F-DAB as reference.
- 25 - Figure 15 shows immunoblot analysis (Western-blot) of the multivalent antigen as qualitatively revealed by type-specific serum polyclonal antibody. Legend of the loaded samples: 1:
- 30

Multivalent conjugate CRM197-3,6A,7F (from line 2 of Fig. 14, above); 2: Mixture of CRM197+Ps3-DAB+Ps6A-DAB+Ps7F-DAB as reference.

- 5 - Figure 16 shows the comparison between the % inhibition (expressed as MIC<sub>50</sub>) for CRM197 native and in its conjugated form as CRM197-Ps,3,6A,7F.
- Figure 17 shows the sigmoidal curve (log scale) referred to the graph of Figure 16.
- 10 - Figure 18 shows the comparison between the % inhibition (expressed as MIC<sub>50</sub>) of Ps 3-DAB and CRM-3,6A,7F vs. native Ps3 showing Type 1 Antigenicity or Antigenic Identity of Ps3 following either DAB activation or conjugation.
- 15 - Figure 19 shows the sigmoidal curve (log scale) referred to the graph of Figure 18.
- Figure 20 shows the comparison between the % inhibition (expressed as MIC<sub>50</sub>) of Ps 6A-DAB and CRM-3,6A,7F vs. native Ps 6A showing Type 1  
20 Antigenicity or Antigenic Identity of Ps6A following either DAB activation or conjugation
- Figure 21 shows the sigmoidal curve (log scale) referred to the graph of Figure 20.
- Figure 22 shows the comparison between the %  
25 inhibition (expressed as MIC<sub>50</sub>) MIC<sub>50</sub> of Ps 7F-DAB and CRM-3,6A,7F vs. native Ps 7F showing Type 1 Antigenicity or Antigenic Identity of Ps7F following either DAB activation or conjugation.
- Figure 23 shows the sigmoidal curve (log scale)  
30 referred to the graph of Figure 22.

In the following experimental section the invention will be disclosed in more detail according to preferred embodiments, that should be considered not to be limitative for the scope of protection but merely for illustrative purpose.

#### EXAMPLES

EXAMPLE 1: Synthesis of the tetravalent conjugate antigen comprising polysaccharides 3, 6A, 7F of *S.pneumoniae* and the carrier protein CRM197

Chemical activation of Ps 3,6A,7F to the homologous Ps-DAB (diamine butyric acid derivative)

This step has been performed according to the process disclosed by the Applicant in the Claim 1 (step A1) of the above mentioned patent EP1501542, herewith included as a reference.

Specific controls of such activation as well as the obtained characteristics of the activate Ps structures is here below reported using  $^1\text{H-NMR}$  spectroscopy.

$^1\text{H-NMR}$  analysis of Ps3-DAB, Ps6A-DAB, Ps7F-DAB

*1. Solution of Ps and Ps-DAB derivatives for NMR analysis*

3-4 mg of polysaccharide sample (PS) or PS-DAB is solved in 0.7 ml of  $\text{D}_2\text{O}$  - phosphate buffer and transferred into a 5 mm NMR tube. The concentration of phosphate buffer prepared in  $\text{D}_2\text{O}$  is 100mM, pH=7. Trimethylsilylpropionic acid sodium salt (TSPA),  $(\text{CH}_3)_3\text{Si}(\text{CD}_2)_2\text{COONa}$  is used as an internal reference. The concentration of TSPA is 1mM.

## 2. NMR equipment

High field NMR spectrometer (600MHz) is used. A high resolution 5 mm probehead with z-gradient coil capable of producing gradients in the z-direction (parallel to the magnetic field) with a strength of at least  $55 \text{ G}\cdot\text{cm}^{-1}$  is employed.

## 3. Setup of NMR experiments

After the introduction of the sample inside the magnet all the routine procedures have been carried out : tuning and matching, shimming, 90 degree pulse calibration. Presaturation can be used to suppress the residual HDO signal. For good presaturation the centre of the spectrum (O1) must be set exactly on the HDO signal (about 4.80 ppm), and good shimming is desirable as well.

After adjustment of parameters for presaturation, the parameters of diffusion gradient experiments are checked. The stimulated echo pulse sequence using bipolar gradients with a longitudinal eddy current delay is used.

## 4. Fingerprinting of DAB-activation

Group  $-\text{CH}_2-\text{NH}_2$  at 3.08 ppm

Group  $-\text{CH}_2-\text{NH}-\text{CH}_2-$  at 3.17 ppm

## 5. % of DAB activation on Ps

Is in the range value of 0.5-5.0 % moles DAB/moles BRU (Basic Repeating Unit of the Group-specific Ps) with an optimal molar range 1.5-3.0 %.

Derivatization of Ps3-DAB, Ps6A-DAB, Ps7F-DAB to their homologous active esters as Ps-DAB-MSE derivatives

This step has been performed according to the process disclosed by the applicant in Claim 8 of the European Patent EP 1501542, herewith included as a reference.

Simultaneous coupling of the three activated (poly-functional) Ps to the (poly-functional) carrier protein CRM197

The chemical synthesis of the conjugate, also known as coupling reaction, has been performed according to the process disclosed by the applicant in claim 8 of the European Patent EP1501542 herewith included as a reference.

The procedure, however, can be here considered as innovative because the three coupling reactions are simultaneously run, rather than proceeding in one coupling reaction at the time (or step-by-step process).

This procedure may be preferred to the step-by-step coupling of each Ps-activated antigen for the simple reason of shorting the reaction time, therefore improving the efficiency of the reaction, provided that the three activated-Ps are in the condition to comparatively compete at the equilibrium for the coupling reaction (this feature include comparable average MW, comparable range of Ps-DAB activation and comparable stoichiometric ratios among the reacting groups of the protein and those of the activated Ps).

The appropriate stoichiometry of reaction keeps in consideration the total amount of succinimidyl esters relative to the three Ps antigens activated and the amino groups of the carrier protein available.

Stoichiometry is preferentially set as to consider the reactivity of no more than 20% (or 8 out of 40) of the amino groups available in the structure of CRM197 (as an example) in order for the protein to optimally  
 5 conserve its antigenic repertoire.

Based on experimental data, the coupling reaction is consistent with the following stoichiometry :



10 Where the entity Ps-DAB-derivatives refer to the total of equal parts of each of the three type-specific carbohydrate structures in reaction yielding a conjugate averaging 1 mole of protein for the total of 3 moles of type-specific Ps carried, plus the due  
 15 excess of Ps-DAB-derivatives, as ruled by the equilibrium constant:

$$K_{eq} = \frac{[\text{CRM197-(DAB-Ps)}_3][\text{Ps-DAB-derivatives}]}{[\text{CRM197}][\text{Ps-DAB-derivatives}]^4} = \frac{[\text{CRM197-(DAB-Ps)}_3]}{[\text{CRM197}][\text{Ps-DAB-derivatives}]^3}$$

The chemical equation makes evidence for the complete  
 20 glycosylation of the CRM197 carrier protein. The equation also shows that the conjugation reaction depends from the concentrations of both reagents, the nucleophile (CRM197 through the epsilon-NH<sub>2</sub> groups of its Lys residues) and the electrophile (the carbonyl  
 25 moiety of the ester groups of Ps-DAB-derivative) therefore being defined as S<sub>N</sub>2 reaction.

The above considerations are consistent with the experimental observation that the highest yield in the glycosylation reaction obtained with CRM197 as carrier

protein has been 100% of the carrier protein and about 80% (w/w) of the Ps-DAB-derivatives present in reaction, with the remaining part of them being a low amount of uncoupled Ps-derivatives necessary for  
5 pushing to the right side the equilibrium.

In this type of reactions, the solvent affects the rate of reaction because solvents may or may not surround the nucleophile, thus hindering or not hindering its approach to the carbon atom. Polar aprotic solvents,  
10 are generally better solvents for this reaction than polar protic solvents because polar protic solvents will be solvated by the solvent's hydrogen bonding for the nucleophile and thus hindering it from attacking the carbon with the leaving group. A polar aprotic  
15 solvent with low dielectric constant or a hindered dipole end, will favor S<sub>N</sub>2 manner of nucleophilic substitution reaction (preferred examples are: DMSO, DMF, tetrahydrofuran etc.). However, in the present case using CRM197 as carrier protein, polar protic  
20 solvents and polar aprotic solvents work very well when experimentally compared vis-à-vis.

The temperature of the reaction, which affects K<sub>eq</sub>, is the lowest compatible with the use of the solvent chosen, when considering that the reaction is a  
25 spontaneous one (therefore being exothermic) and therefore is generally set between a temperature of 4° and 20°C.

In addition to the conjugation chemistry above detailed, other chemistries can be used to achieve the  
30 synthesis of the multivalent conjugate antigen; among these, the direct coupling of the protein (via reductive amination) to the oxidized Ps (via O-de-

hydrogen uncoupling) or the use of heterologous and chemically complementary linkers that may serve to activate the Ps and the protein.

Also, in addition to the strategy of using chemistries  
5 leading to obtain multivalent cross-linked protein-Ps conjugates via the poly-functionality of the protein and that of the Ps components, one may consider the synthesis of the presently disclosed antigenic multivalent molecular construct as based on  
10 oligosaccharides activated at their end-reducing group for then being coupled to the carrier protein, as the applicant did show earlier in another model of conjugate antigen in the above mentioned paper Porro M. et al. in *Molecular Immunology*, 23: 385-391, 1986,  
15 herewith enclosed as a reference.

Finally, the disclosed molecular construct might be thought to be prepared by enzymatic glycosylation in bacterial or yeast cells or other engineered living cells, using "ad hoc" DNA-recombinant techniques.

20

EXAMPLE 2: Physical-chemical analysis of the antigenic multivalent molecular construct CRM197-3,6A,7F

The GPC (Gel Permeation Chromatography) analysis has been employed to perform the physical analysis of the  
25 antigenic multivalent molecular construct of Example 1. Figure 10 shows GPC analysis of the multivalent antigen as it is obtained from the conjugation reaction, before purification. The chromatogram comes from Sepharose 4B-CL equilibrated in 0.14 M NaCl  
30 buffered at pH = 7.50. Purification of the multivalent antigen is simply obtained by collecting and pooling the eluted fractions from  $K_d = 0.00$  to  $K_d = 0.30$ .

The technique of SEC-MALLS helps to define the dispersity ( $\mathcal{D}$ ) of the molecular system obtained, calculated using the equation  $\mathcal{D} = M_w/M_n$ , where  $M_w$  is the mass-average molar mass and  $M_n$  is the number-average molar mass and also allows to determine some intrinsic properties of the above molecular system since the intensity of the light scattering angles carries information about the molar mass, while the angular dependence carries information about the size of the macromolecule. In fact, if a given macromolecule of mass  $M$  is made up of elements  $m_i$ , then the basic light scattering equation shows that :

$$\langle r_g^2 \rangle = \frac{\sum_i r_i^2 m_i}{\sum_i m_i} = \frac{1}{M} \sum_i r_i^2 m_i$$

where  $r_i$  is the distance of element  $m_i$  from the center of mass of the molecule of total mass  $M$ . According to this equation, the relationship between mass, size, and the quantities measured is defined. The following Table 1 shows the characterization of the dispersed molecular mass of the above purified multivalent antigen (fractions in the range  $K_d = 0.00 - 0.30$ ) analyzed by SEC-MALLS.

TABLE 1

Upper Mass (g/mol)	Average Mass (g/mol)	Lower Mass (g/mol)
$5.92 \times 10^6$	$9.67 \times 10^5$	$2.69 \times 10^5$
(66.4 %)	(26.6 %)	(7.0%)

25

The experimental data collected by SEC-MALLS show that the dispersed mass of the antigenic multivalent molecular construct encompasses the basic unit  
5 [CRM197-3,6A,7F]<sub>n=1</sub> for about 7% of the mass dispersion, and polymers of it with composition [CRM197-3,6A,7F]<sub>n=3.6</sub>, for about 27% of the mass dispersion, and up-to [CRM197-3,6A,7F]<sub>n=22</sub> for the rest of the mass dispersion which represents the main form (66%) of the  
10 molecular construct in terms of product of reaction. Polymers of the basic unit of the molecular construct are obtained as cross-linked molecular entities because of the polyfunctionality of the Ps antigens (about 2% of DAB activation, on molar basis, as shown by <sup>1</sup>H-NMR  
15 spectroscopy) and the polyfunctionality of the carrier protein (40 reactive amino groups / mole, available as 39 Lysine residues + 1 amino terminal aa within the structure encompassing the whole 535 aa of the sequence).

20 Figure 11 shows the GPC analysis, as an example, on the same gel Sepharose 4B-CL of the four components just mixed together (CRM197 + Ps 3-DAB + Ps 6A-DAB + Ps 7F-DAB) in order to show absence of any significant amount of complex formation among the single antigens.

25 Chemical methods for titration of the three Ps structures involved the analysis of uronic acid (type 3), phosphorous (type 6A) and hexosamines (type 7F) according to the requirements of the WHO guidelines.

30 The following Table 2 shows the characterization of the dispersed molecular masses of the three mixed type-specific Ps-DAB derivatives as analyzed by SEC-MALLS, for reference.

TABLE 2

Upper Mass (g/mol)	Average Mass (g/mol)	Lower Mass (g/mol)
2.75x10 <sup>5</sup>	7.27x10 <sup>4</sup>	1.81x10 <sup>4</sup>
(17.0 %)	(70.5 %)	(12.5%)

Considering the different BRU of the three Ps structures, the mean number ± SD of BRU/Ps is 112 ± 62

Figure 12 shows SEC-HPLC analysis of the multivalent antigen, following purification on Sepharose 4B-CL, with specific reference to the profile of the carrier protein CRM197.

The following experimental conditions were used in the SEC-HPLC analysis:

Column: Phenomenex, Biosep-SEC-S3000, 300x7.80 mm (Vo 6.92 min.; Vt 12.5 min.)

MW Sizing range: 700 K-5 K

Eluent: NaCl 0.14M + NaH<sub>2</sub>PO<sub>4</sub> 0.05M pH 6.80

Flow: 1 ml/min

Detector: 280 nm (detection of the protein CRM197)

Figure 13 shows SEC-HPLC analysis of CRM197 as native protein, when mixed with Ps 3-DAB , Ps 6A-DAB and Ps 7F-DAB. Experimental conditions are the same as above reported for the analysis carried out in Figure 12.

In light of the above the conjugate under analysis is a polydispersed, monomeric to polymeric, molecular entity which contains the basic unit of the molecular construct reported in the chemical equation [CRM197-(Ps)<sub>3</sub>], with a calculated average MW of ca. 2.7 x 10<sup>5</sup> when considering the average MW (estimated by SEC-

MALLS) of the poly-functional DAB-activated Ps structures (ca.  $0.7 \times 10^5$ ) and that of CRM197 ( $5.85 \times 10^4$ ) accounting for 535 aa); accordingly, the several cross-linked units of such basic structure is reaching a MW  
5 of ca. 6 millions as evaluated by SEC-MALLS. The w/w ratio between the carrier protein and each of the three type-specific Ps is ca. 1.0; this w/w ratio yields an average molar ratio (R) protein/type-specific Ps of 1.0, corresponding to an average ratio of one mole of  
10 protein/mole of type-specific Ps, as well suggested by the chemical equation.

Accordingly, the experimentally obtained, cross-linked, molecular entity responds to a molecular model constituted by several polymeric units of the basic  
15 unit just consisting of one mole of carrier protein carrying a total of three moles of type-specific Ps (one mole for each type-specific Ps).

EXAMPLE 3: Immunochemical analysis of the antigenic  
20 multivalent molecular construct CRM197-3,6A,7F

The immunochemical analysis of the antigenic multivalent molecular construct CRM197-3,6A,7F was carried out by SDS-PAGE using the analytical conditions according to Laemmli U.K., Nature 227, 680-685 (1970),  
25 herewith enclosed as reference.

Figure 14 shows the SDS-PAGE analysis (9% Glycine buffer) showing the pattern of the purified multivalent antigen.

Figure 15 shows immunoblot analysis (Western-blot) of  
30 the multivalent antigen as qualitatively revealed by type-specific serum polyclonal antibody. The analytical conditions employed were according to Towbin H. et al.,

PNAS 76: 4350-4354 (1979). Silver staining according to Porro M. et al., *Anal. Biochem.* 118: 301-306 (1981). The serum polyclonal, Ps type-specific, antibodies are described in the below section dedicated to the inhibition-ELISA method.

5 Qualitative and quantitative determination of each antigenic Ps component on the basis of inhibition-ELISA using polyclonal (or monoclonal) antibodies

As well known since the birth of Immunochemistry, branch of the wider field of Immunology in the Thirties' of the past Century, capsular Ps antigens are composed of Basic Repeating Units (BRU) which may be constituted by homologous monosaccharides (e.g.: meningococcal Ps) as well as by more complex hetero-  
15 polysaccharide sequences involving bi/tri/tetra/penta/esa/epta-saccharide residues (e.g.: pneumococcal Ps). An average sequence of 5 (preferably 8) to 12 monosaccharide residues form the basic structural epitope of (Ps) carbohydrate antigens, which confer the due immunological specificity to each (Ps) structure. This size, typical of a single epitope within the human ABO system or of a sequence of epitope-repeating structures within complex bacterial capsular Ps, is coherent with the size of the binding site of an antibody (Kabat E.A., "The nature of an antigenic determinant" *J. Immunol.* 97: 1-11, 1966) and, on these basis, it was possible to describe the reactivity of a Ps structure toward a specific polyclonal population of antibodies, by inhibiting the  
20 binding reaction of the system Ps-Ab using different MW of the Ps polydispersed system, in order to document the relation existing between antigenicity of a Ps  
25  
30

structure containing repeating BRU (thus forming repeated epitopes of identical antigenicity) and the specificity for it of the homologous polyclonal antiserum (Porro M. et al, *Mol. Immunol.*22 : 907-919, 5 1985) ; by comparison of the MIC50 of the various MW of the polydispersion of a given Ps, it was then possible to define the relative specificity of a polyclonal (or monoclonal) population of antibodies for such MW and finally calculating the relative concentration of the 10 different Ps structures for a quantitative determination of it.

By having a reliable immunochemical method for mapping and titering the Ps structures present in such a molecular construct, there are practical advantages of 15 determining the qualitative and quantitative characteristics of such model of conjugates, over the chemical methods, especially in cases of Ps with very close structural features for their sequences, like in the case of type 6A and 6B or type 19A and 19F or in 20 any other case where structural similarities among Ps antigens are present as in the case of type-specific Ps belonging to a given reference group (e.g.: Group 6 includes the type-specific Ps 6A,6B,6C,6D; Group 19 includes the type-specific Ps 19A,19B,19C,19F; Group 23 25 includes the type-specific Ps 23A,23B,23F). In fact, the exquisite specificity of an antibody can easily discriminate between such structural similarities without ambiguity and in short time, unlike chemical methods.

30 The recent development of monoclonal antibodies to the Ps antigens of *S.pneumoniae* (Pride M.W. et al., *Clin. And Vaccine Immunol.* 19(8): 1131-1141, 2012) would

further increase the potential of this powerful method of analysis.

The comparison between chemical titration and immunochemical titration of carbohydrate antigens for testing their quantitative equivalence, is performed by the use of inhibition-ELISA, through the experimentally determined parameter MIC<sub>50</sub> (Minimal Inhibitory Concentration of the selected carbohydrate antigen working as inhibitor of the homologous reference Ps-Ab reaction) in order to evaluate accuracy and precision of the immunochemical method with respect to the chemical one in the analytical control of such a kind of molecular construct.


*Inhibition-ELISA protocol*

The following ELISA protocol was applied in order to determining the value of MIC<sub>50</sub> of each of the three Ps-DAB derivatives and the protein CRM197 or the multivalent conjugate CRM197-3,6A,7F as inhibitors of the homologous reference reaction type-specific Polysaccharide-Antibody (Ps-Ab) or Protein-Antibody (Prot-Ab).

Reference type-specific Ps-derivative (Ps-DAB) and the multivalent conjugate CRM197-3,6A,7F were prepared according to the mentioned process reported by Porro M. in claim 8 of the Patent EP1501542.

Chemical methods for titration of the three Ps structures involves analysis of Uronic acid (type 3), Phosphorous (type 6A) and Hexosamines (type 7F) according to the requirements of the WHO guidelines. The inhibition reaction is based on the principle for a given carbohydrate structure, of a given molecular

mass, of inhibiting the homologous reference reaction system according to the immunochemical equation :



10 So that the difference in reactivity between the reference reaction and the inhibited-one is representative for the different or identical specificity of the antibody population for the inhibitor. By using carbohydrate structures of  
 15 different molecular mass, one can describe the sigmoidal curve typical of that specific reaction and calculate the MIC<sub>50</sub> of the inhibitor for then comparing it with the one of the carbohydrate structure of reference and establishing the parameter of  
 20 Antigenicity of the inhibitor (on qualitative basis) and Specificity of the antibody (on quantitative basis). All these concepts and the relative practical use are reported in the following publications, herewith incorporated as references:

25

- Berzofsky J.A. and Schechter A.N. Mol. Immunol., 18: 751-763 (1981);
- Porro M. et al. Mol. Immunol., 22 : 907-919 (1985).

30

Method of analysis (illustrative)

## Stock Solutions :

- Ps-DAB or CRM197 at 1 mg/ml in PBS pH 7.2-7.4
  - o PBS 1x (1L)
    - 5 • 8.0 g NaCl
    - 0.31 g  $\text{KH}_2\text{PO}_4$
    - 2.06 g  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$
    - 0.16 g KCl
    - Do not adjust pH
- 10 • TBS-Brij 0,1% (v/v)
  - o TBS 10x (1l)
    - 15 • 80 g NaCl
    - 1.6 g KCl
    - 0.94 g Tris
    - 14.56 g Tris-HCl
    - 33 ml Brij-35 (30%v/v)
    - Stable at r.t. for 12 months
    - 20 • Dilute 50 ml buffer to 500 ml MilliQuf water
- PBS-Tween20 0,05% (v/v)
- Goat Anti-Mouse IgG or IgM peroxidase labeled
- 25 • Phosphate-Citrate Buffer 0,05M pH 5.0
- $\text{H}_2\text{O}_2$  30% (v/v)
- O-Phenilenediamine 1 mg/ml in Phosphate-Citrate Buffer 0,05M pH 5.0
- 30 •  $\text{H}_2\text{SO}_4$  3M

Procedure:

1. Coating Plates (GREINER 65001 polystyrene plate SIGMA cod. M4436)
  - Ps at 20  $\mu\text{g}/\text{ml}$  PBS pH 7.4 37°C 2 h + o.n. 4°C.
  - 35 - CRM197 at 10  $\mu\text{g}/\text{ml}$  PBS pH 7.4 o.n. 4°C.
  - Coat 100  $\mu\text{l}/\text{well}$
2. Washing 5x with TBS-Brij 0,1% (v/v) (1<sup>st</sup> wash 20

sec.)

3. Pneumococcal reference polyclonal antisera from Statens Serum Institute, Copenhagen, DK ([www.ssi.dk](http://www.ssi.dk)) in PBS-Tween 0,05% (v/v) 2h 37°C. Final dilutions (as
- 5 examples):
- a. Rabbit antiserum to group 3 1:100,000 v/v  
(Positive~1.0 OD490<sub>nm</sub>)
  - b. Rabbit antiserum to group 6A1:25,000 v/v  
(Positive~1.0 OD490<sub>nm</sub>)
  - 10 c. Rabbit antiserum to group 7F 1:800,000 v/v  
(Positive~1.0 OD490<sub>nm</sub>)
4. Unknown samples: the unknown samples are interpolated versus the reference sigmoidal regression curve obtained by the reference reaction.
- 15 5. Murine serum anti-CRM197, final dilution, 1:100,000 v/v (Positive ~1.0 OD490<sub>nm</sub>).

TABLE 3

Inhibitor final/well	Inhibitor stock solution										Anti-Ps stock solution	
	1 ng/ml	10 ng/ml	100 ng/ml	1 µg/ml	10 µg/ml	100 µg/ml	200 µg/ml	400 µg/ml	1 mg/ml	2 mg/ml		
0.5 ng/ml	50 µl											50 µl
5 ng/ml		50 µl										50 µl
50 ng/ml			50 µl									50 µl
0.5 µg/ml				50 µl								50 µl
5 µg/ml					50 µl							50 µl
50 µg/ml						50 µl						50 µl
100 µg/ml							50 µl					50 µl
200 µg/ml								50 µl				50 µl
500 µg/ml									50 µl			50 µl
1 mg/ml										50 µl		50 µl

- 6. Incubation x Inhibition time: 15min
- 7. Washing 5x with TBS-Brij 0.1% (v/v) (1<sup>st</sup> wash 20 sec.)
- 8. Goat Anti-Rabbit or anti Mouse IgG peroxidase  
5 labelled in PBS-Tween 0.05% (v/v) 2h 37°C
- 9. Washing 5x with TBS-Brij 0.1% (v/v) (1<sup>st</sup> wash 20 sec.)
- 10.0-Phenilenediamine 1 mg/ml in Phosphate-Citrate Buffer 0.05M pH 5.0, H<sub>2</sub>O<sub>2</sub> 0.03% (v/v)
- 10 11.After 5' Stop the reaction with H<sub>2</sub>SO<sub>4</sub> 3M 50 µl/well
- 12.Read at OD 490 nm
- 13. Interpolate unknown values vs the reference sigmoidal line regression obtained by the reference reaction:

15

Calculation of % inhibition :

$$\frac{\text{Inhibited OD Value-Blank OD value}}{\text{Positive OD Value-Blank OD value}} \times 100 = (\%)$$

20

Thus, % Inhibited = 100 - (%)

25 Calculation of MIC<sub>50</sub>:

This inhibitory concentration is determined at 50% of either the regression function or the related sigmoidal curve. Method's SD is within 20% of the mean value.

RESULTS

30 The results of the MIC50 for CRM197 native and in

its conjugated form as CRM197-Ps,3,6A,7F show that the conjugation reaction did not affect the antigenic features of CRM197 (Type 1 Antigenic Identity), as may be inferred from the analysis of the graphs set forth  
5 in Figure 16-17. Figure 17 illustrates the non-linear regression function of the sigmoidal curve.

The results of the MIC50 for each of the three conjugated Ps-DAB derivatives are illustrated in the graphs set forth in Figures 18-23. Figures 19, 21 and 23  
10 illustrate the non-linear regression function of the sigmoidal curve.

EXAMPLE 4: *Determination of the concentration for the carbohydrate antigen in either activated or multivalent  
15 conjugated form: comparison of chemical titration vs. immunochemical titration*

Immunochemical titers are obtained according to the method reported above in Example 3 dedicated to the Inhibition-ELISA method; chemical titers are obtained  
20 according to the methods above reported in Example 2; immunochemical titers of unknown samples of each of the three carbohydrate-specific antigens, either in activated or conjugated form, were determined by interpolation on the linear part of a reference  
25 standard curve built by inhibition-ELISA using known, chemically titred, carbohydrate antigen amount. The reported values are the mean of several independent assays. Results on determination of quantitative equivalence of the two methods are summarized in the

following Table 4.

TABLE 4

Chemical determination (µg/ml)	Immunochemical determination* (µg/ml)
Ps1 1.0	0.9 (- 10.0%)
2.0	2.3 (+ 13.1%)
4.0	3.7 (- 7.5%)
*Lowest amount Ps1 detected: 0.02 ug	
Ps3 0.80	0.91 (+13.4%)
1.60	1.77 (+10.6%)
3.20	3.31 (+3.4%)
6.40	6.71 (+ 4.8%)
*Lowest amount Ps3 detected: 0.01 ug	
Ps4 2.0	2.25 (+ 11.2%)
4.0	3.80 (- 5.0%)
8.0	7.40 (- 7.5%)
*Lowest amount Ps4 detected: 0.01 ug	
Ps5 3.1	3.3 (+ 6.1%)
6.25	5.7 (- 8.8%)
12.5	10.8 (- 13.6%)
*Lowest amount Ps5 detected: 0.015 ug	
Ps6A 0.63	0.60 (-4.8%)
1.72	1.92 (+11.6%)
3.43	3.63 (+5.8%)
6.87	7.31 (+6.4%)
*Lowest amount Ps6A detected: 0.01 ug	
Ps6B 2.0	2.4 (+ 16.7%)
4.0	4.3 (+ 7.0%)
8.0	9.2 (+ 13.0%)
*Lowest amount Ps6B detected: 0.10 ug	

5	Ps7F	1.34	1.43 (+6.7 %)
		2.68	3.00 (+11.9 %)
		5.37	5.47 (+1.9 %)
		10.75	11.07 (+ 3.0 %)
*Lowest amount Ps7F detected: 0.01 ug			
10	Ps9V	3.8	4.2 (+ 9.6 %)
		7.5	6.4 (- 15.0 %)
		15.0	12.2 (- 18.7 %)
	*Lowest amount Ps9V detected: 0.10 ug		
15	Ps14	3.4	3.8 (+ 10.6 %)
		6.8	6.5 (- 5.0 %)
		13.5	16.2 (+ 16.5%)
	*Lowest amount Ps14 detected: 0.10 ug		
20	Ps18C	2.5	2.8 (+ 10.8 %)
		5.0	4.7 (- 6.0 %)
		10.0	8.9 (- 11.0 %)
	*Lowest amount Ps18C detected: 0.02 ug		
25	Ps19A	3.8	4.1 (+ 8.7 %)
		7.5	6.5 (- 13.4 %)
		15.0	13.3 (- 11.4 %)
	*Lowest amount Ps19A detected: 0.02 ug		
	Ps19F	3.8	3.5 (- 7.9 %)
		7.5	8.3 (+ 9.4 %)
		15.0	17.0 (+ 11.8 %)
	*Lowest amount Ps19F detected: 0.02 ug		
	Ps23F	3.8	4.3 (+ 11.7 %)
		7.5	6.6 (- 12.0 %)

	15.0	13.3 (- 11.4 %)	
*Lowest amount Ps23F detected: 0.02 ug			
CRM <sub>197</sub>	1.3	1.2 (- 7.7 %)	
	2.5	2.7 (+ 11.7 %)	
	5.0	5.3 (+ 5.7 %)	5
	10.0	9.6 (- 4.0 %)	
*Lowest amount CRM <sub>197</sub> detected: 0.10 ug			
*Lowest amount immunochemically detectable for the type-specific Ps in the assay conditions.			

10

Note: Physical-chemical determination of the protein CRM197 was performed by Folin reagent and/or amino acid analysis using hydrophobic reverse-phase HPLC to separate fluorescein-labeled amino acids following acid hydrolysis (Pico-Tag method by Millipore). SD for the physical-chemical determinations is within 10% of the mean values; SD for the immunochemical determinations is within 20% of the mean values, that is within the estimated SD of the day-by-day variation of the ELISA method and in agreement with the guidelines of the European Pharmacopoeia 5th Edition (2008) for the Pneumococcal Polysaccharide Conjugate Vaccine.

The same methodology described for the qualitative and quantitative immunochemical analysis of each molecular construct above reported, is then used for characterization of the final formulation of the polyvalent vaccine containing the association of several (4 or 5 or 6 or more) molecular constructs in order to get the complete characterization of an exemplificative 12-valent or 15-valent or 18-valent vaccine.

EXAMPLE 5: Immunological analysis in a murine model of the antigenic multivalent molecular construct, as an example

Vaccine Formulation

5 Mean ratio Protein / each of the type-specific Ps: 1.1 ± 0.1 (w/w).

Dose of the molecular construct CRM197-3,6A,7F

The injected dose is 0.01 µg and 0.1 µg of each type-specific conjugated Ps, with and without AlPO<sub>4</sub> as  
10 adjuvant at the fixed dose of 0.5 mg/dose (equivalent to ca. 0.120 mg of Alum). Adsorption of the multivalent molecular construct to the mineral adjuvant occurred at ≥ 80 % , on weight basis, as estimated by ELISA.

According to the stoichiometry of the multivalent  
15 conjugate, the total dose of CRM197 is ca. 0.01 µg in the case of the lowest dose of each type-specific conjugated Ps and ca. 0.1 µg in the case of the highest dose of each type-specific conjugated Ps.

It is remarked that the dose injected of 0.01 µg Type-specific  
20 specific Ps is the lowest-one, immunogenic in mice, which is acknowledged by US-FDA and EMEA for the currently licensed pneumococcal conjugate vaccines, which use Aluminum Phosphate as adjuvant.

Animals

25 Each group of animals containing 10 female Balb/c mice (alternatively CD1) and 6 female New Zealand white rabbits.

Route

i.p. (mice) and s.c. (rabbits)

Immunization schedule

0, 2, 4 weeks; bleeding at week 0, 2, 4, 6 (mice).

0,4 weeks; bleeding at week 0,4,6 (rabbits).

Control immunization with plain Ps antigens were  
5 omitted on the basis of the historical knowledge that  
highly purified Ps antigens are not significantly  
immunogenic in mammals and do not "boost" IgG  
isotype antibodies following repeated injections of it.

ELISA titers

10 Titers expressed as end-point reaction showing O.D.  $\geq$   
2.0 relative to the control reactions for each type-  
specific Ps and CRM197 or DT (Diphtheria Toxoid), the  
antigen immunogenically identical and in statistical  
correlation with CRM197 (Porro M. et al. J. Infect.  
15 Dis., 142 (5), 716-724, 1980). Sera pool dilutions are  
performed serially, in twofold fashion, starting from  
dilution 1/200.

MOPA (functionality assay)

For testing Opsonic activity of the murine and rabbit  
20 polyclonal antibodies raised following immunization  
with the multivalent molecular construct, the MOPA-4  
test (4-fold Multiplexed Opsono Phagocytic killing  
assay) was run, as recommended by WHO guidelines, using  
HL60 cells. Titers expressed as geometric mean of the  
25 end-point dilution showing  $\geq 50\%$  killing activity for  
each sera pool at each dose, as referred to a standard  
curve built in parallel for calculating the titer  
values of the various samples by linear interpolation.

IMMUNOLOGICAL RESULTS

Dose of 0.01 µg Ps/type-specific conjugated Ps. Geometric Mean Titers of IgG or IgM to type-specific Ps or to CRM197 in murine sera pool as determined by ELISA. SD is within ± 25 % of the reported Geometric Mean. MOPA titers are reported in parenthesis as calculated by linear interpolation in the assay procedure. Unless otherwise indicated, the statistical significance among sera titers (determined by t-test) was < 0.01. Results are summarized in the following Table 5.

TABLE 5

Ag	Without Adjuvant				With Adjuvant			
	W0	W2	W4	W6	W0	W2	W4	W6
<b>3</b>	<200	<200	200	800	<200 <200	200 <200	800 <200 (12)	3,200 <200 (124)
<b>6A</b>	<200	<200	200	800	<200 <200	200 <200	400 <200 (6)	3,200 <200 (135)
<b>7F</b>	<200	<200	200	800	<200 <200	200 <200	1,600 200 (26)	6,400 400 (248)
<b>CRM197</b>	<200	<200	800	3,200	<200 <200	1,600 200	12,800 800	25,600 800

Dose of 0.10 µg/type-specific conjugated Ps. Geometric Mean Titers of IgG or IgM to type-specific Ps or to DT in murine sera pool as determined by ELISA. SD is

within  $\pm 25\%$  of the reported Geometric Mean. MOPA titers are reported in parenthesis as calculated by linear interpolation in the assay procedure. Results are summarized in the following Table 6.

5

TABLE 6

Type Ps	Without Adjuvant				With Adjuvant			
	W0	W2	W4	W6	W0	W2	W4	W6
<b>3</b>	<200	200	800	6,400	<200 <200	800 200 (16)	6,400 400 (254)	25,600 800 (1,824)
<b>6A</b>	<200	200	800	3,200	<200 <200	800 200 (22)	3,200 200 (120)	12,500 800 (1,150)
<b>7F</b>	<200	200	1,600	3,200	<200 <200	1,600 200 (48)	6,400 400 (168)	25,600 800 (1,580)
<b>CRM197</b>	<200	800	3,200	12,800	<200 <200	6,400 200	25,600 800	102,400 1,600

The above Tables 5 and 6 show the anamnestic induction of biologically functional IgG isotype antibodies for each of the four components of the multivalent molecular construct.

Particularly, any boosting activity on the immune system observed for the carrier protein is in parallel observed for each of the carried Ps antigens, typical and well known behavior of helper T-dependent antigens. The effect of the mineral adjuvant is particularly evident at such low doses of the multivalent antigen,

another feature of helper T-dependent antigens like proteins which do generate a stronger immune response taking further advantage from the antigen slow-release over time in the host's body.

5 Furthermore, the effect of glycosylation on the carrier protein CRM197, as generally known for glycoproteins, can be beneficial for the improved resistance of this protein to proteolytic enzymes, since CRM197 is a fragile protein when exposed to the serine proteases  
10 widely present in mammals (Porro M. et al., J. Infect. Dis., 142 (5), 716-724, 1980).

The booster effect obtained against CRM197 also strongly supports the fact that the multivalent molecular construct has the potential to work as  
15 antigen in humans for the prevention of toxicity due to diphtheria toxin, a well documented property of CRM197 in animal models (see the above bibliographic reference), in which case the multivalent antigen might be also used for the immunization of infants and young  
20 children in replacement of the diphtheria toxoid vaccine (present in the DTP vaccine) so that the antigenic burden of the paediatric vaccines in use could be further reduced. Finally, according to the immunological features of helper T-dependent antigens,  
25 IgM isotype antibody were neither significantly induced nor boosted by the carrier protein or the carried Ps of the multivalent molecular construct.

Rabbit sera were specifically used to assess the four-fold increase of IgG isotype antibody ELISA titers to  
30 type-specific Ps, with the parallel increase of OPA titers, following the first booster dose of the molecular construct. The following results were

collected, expressed as fold-increase of the sera GMT obtained with respect to the titers detected following the immunological priming dose and reported in the following Table 7.

5

TABLE 7

Type Ps	IgG Ab to Ps (fold increase)	OPA to Ps (fold increase)
3	12	40
6A	18	48
7F	28	52

EXAMPLE 6: Vaccine formulation of a Quadrivalent Meningococcal Conjugate Vaccine (QMCV) and of an up-to 25-valent Pneumococcal Polyvalent Conjugate Vaccine (PPCV)

The composition/formulation of QMCV may be limited to one single molecular construct where one mole (or fractions of it) of carrier protein carries at least one mole (or fractions of it) of each of the four different carbohydrate structures. The related pondered amount of the multivalent antigen depends upon the selected MW of the activated carbohydrate structures which may vary from LMW haptens constituted by a few (8-12) monosaccharide residues or BRU (Basic Repeating Units) encompassing the respective basic epitopes [Porro M. et al. *Molecular Immunology*, 22 : 907-919 (1985); Porro M. et al. *Molecular Immunology*, 23: 385-391 (1986)] and up-to HMW carbohydrate structures composed of 200 BRU or more for containing the repeated structure of the basic epitope.

In such a case the amount of carrier protein per human

dose, can be reduced to at least 25 % of the amount present in a formulation which uses the association of single, group-specific, conjugates.

The composition of PPCV depends from its polyvalent formulation. For instance, for a 15-valent vaccine containing selected 15 serotypes or for a 18-valent vaccine containing selected 18 serotypes, as above considered, only five to six entities of the multivalent antigenic molecular construct will be necessary, since in each of them, one mole (or fractions of it) of carrier protein will carry an average of one mole (or fractions of it) of each of three different type-specific carbohydrate structures. The related pondered amount of the multivalent antigen depends upon the selected MW of the activated carbohydrate structures which may vary from LMW haptens constituted by a few BRU (Basic Repeating Units) encompassing the respective epitopes (Arndt B. and Porro M. in : Immunobiology of Proteins and Peptides, Edited by M.Z. Atassi, Plenum Press, New York and London, pg. 129-148, 1991) and up-to HMW carbohydrate structures composed of 200 BRU or more for containing the repeating structure of the basic epitope. In any case the amount of carrier protein per human dose, can be reduced to at least 30 % of the amount present in a formulation which uses the association of single, type-specific, conjugates.

New emerging serotypes of *S.pneumoniae* according to the public available data on epidemiology and antibiotic resistance, are type 6C, 6D (Satzke C. et al., J. Clin. Microbiol., 48(11): 4298, 2010; Yao KH et al., Diag. Microbiol. Infect. Dis., 70(3):291-8, 2011); serogroups

11 (type 11A, 11B, 11C, 11F) (Richter S. et al., Clin. Infect. Dis., 48:23-33, 2009); Calix J.J. et al. J.Bacteriol. 193:5271-5278, 2011); serogroup 15 (type 15B and type 15C); type 23A, serogroups 33 (33F) and 35  
5 (type 35B) (Swanson D., IDSA meeting, Boston, 2011); such antigen Ps might be likely included in a further up-dated broad-spectrum vaccine formulation prepared according to the molecular construct disclosed in the present Application.

10 While the presently licensed 13-valent vaccine covers about 61% of IPD in children younger than 5 years, an up-dated formulation containing the Ps from the newly emerging types of *S.pneumoniae*, might well elevate the bar on coverage to 75-80%; in fact, it has been  
15 estimated that a formulation containing the 23 -valent types of Ps today present in the polysaccharide-based vaccine, accounts for 88% of the bacteremic pneumococcal diseases which then cross-react with types of Ps causing an additional 8% of disease due to  
20 *S.pneumoniae* (source US-Center for Disease Control: www.cdc.gov.). Such kind of up-dated, very broad, formulations can be safely prepared by the use of molecular constructs of the present invention, which allows a reduced use of protein carrier for carrying  
25 such an increased number of Ps antigens. For instance, when considering the dose of 2 µg of CRM197 (similar to *Prevnar* composition)/molecular construct, six molecular constructs carrying 18 Ps antigens would contain a total amount of 12 µg of protein, that is ca. 40 % of  
30 that present in the 13-valent *Prevnar* vaccine, composed of single-conjugates of each type-specific Ps antigen. As specifically referred to an exemplified formulation

of PPCV containing a 15-valent formulation which includes nowadays the most prevalent, epidemiologically significant, type-specific capsular polysaccharides of *S.pneumoniae*, the following molecular constructs have  
5 been synthesized and analyzed as an extended exemplification of the preferred embodiments, according to the methods reported above in Example 1, 2 and 3 for the molecular construct CRM197-3,6A,7F. The total amount of carrier protein exemplified in this  
10 exemplified 15-valent vaccine prepared and formulated according to the procedures reported in this application and defined by the stoichiometry of the resulting five molecular constructs, each one expressing built-in multiple epitopes, is coherent with  
15 the following molar composition relatively to the dose of each molecular construct containing ca. 1 ug of CRM197 carrier protein (MW = 58.5 K) and ca. 1 ug of each of the three selected DAB-activated, type-specific, polysaccharide antigens (average MW = 70.0 K  
20 based on two different criteria of analysis, that is estimating sizing by molecular filtration on calibrated filter membranes and estimating sizing by SEC-MALLS, in all cases using reference carbohydrate molecules like Dextrans of various MW).

25

30

TABLE 8

Molecular construct	Average (w/w) ratio	Average molar
	CRM197/Ps	ratio CRM197/Ps*
CRM197-3, 6A, 7F	CRM197/Ps3 = 1.20	1.44
	CRM197/Ps6A = 0.98	1.17
	CRM197/Ps7F = 1.09	1.30
CRM197-5, 9V, 19F	CRM197/Ps5 = 1.03	1.23
	CRM197/Ps9V = 0.93	1.11
	CRM197/Ps19F = 1.05	1.26
CRM197-1, 14, 19A	CRM197/Ps1 = 1.19	1.42
	CRM197/Ps14 = 0.97	1.16
	CRM197/Ps19A = 0.92	1.10
CRM197-22F, 23F, 33F	CRM197/Ps22F = 1.00	1.20
	CRM197/Ps23F = 1.14	1.37
	CRM197/Ps33F = 1.11	1.32
CRM197-4, 6B, 18C	CRM197/Ps4 = 1.18	1.41
	CRM197/Ps6B = 1.19	1.42
	CRM197/Ps18C = 1.08	1.20

In the exemplified molecular constructs, the Mean of  
5 the (w/w) Protein/type-specific Ps ratio is:  $1.07 \pm$   
 $0.097$  (9.1%) corresponding to the Mean of the (mol/mol)  
ratio:  $1.27 \pm 0.12$ .

In the case when the carrier protein selected is CRM197  
and the average MW of each Ps antigen is twice of the  
10 above reported value, or 140 K, the molar ratio protein

to each Ps increases to an average of 2.5; in contrast, when the average MW of each Ps antigen is half of the above reported value, or 35 K, the molar ratio protein to each Ps decreases to an average of 0.64.

5 The concept of calculating and comparing the features of conjugate antigens on molar basis is fundamental because the immune system processes antigens on molar basis, as Nature does in each chemical or biochemical reaction of transforming matter, therefore referring to

10 the antigen's MW. Accordingly, depending from the average MW of each type-specific Ps antigen and that of the protein carrier, the molar ratios of conjugate antigens are subject to change by the selection of their antigen components. It is mostly preferred that

15 molar ratios between carrier protein and each type-specific Ps antigen be equal to or higher than 1.0 for a likely optimal expression of helper T-dependency. In addition to this molar parameter, it is also important considering the average amount of covalent bonds

20 interposed between the protein and each type-specific carbohydrate antigen, which parallels the activation rate of the type-specific polysaccharide, since this hybrid molecular region is the one experimentally suggested as responsible for the acquired helper T-

25 dependent properties of a conjugate molecule (Arndt and Porro, 1991).

According to the above considerations, another way to change the stoichiometry, and therefore the molar ratio among the components (the carrier protein and each of

the carried carbohydrate antigens) of the molecular construct, without changing the average MW of the Ps antigens selected, is the one which refers to the following exemplified molecular model. This model was  
5 synthesized by virtue of a modified stoichiometry in the reagents of the chemical reaction above reported, in favor of the protein component which was present in reaction at the reversed (w/w) ratio of the reaction reported in the above chemical equation, with each of  
10 the Ps-activated antigens, in order to make evidence of the flexibility of such chemical reaction which may also lead to a product showing the molar ratio between the carrier protein and the carried Ps antigens in favor of the former component. When referring to the  
15 vaccine dose related to the stoichiometry of this exemplified molecular construct, it still contains ca. 1.0 ug of CRM197 carrier protein (MW = 58.5 K) but only ca. 0.3 ug of each of the three selected DAB-activated, type-specific, polysaccharide antigens (average MW =  
20 70.0 K).

TABLE 9

Molecular construct	Average (w/w) ratio	Average molar
	CRM197/Ps	ratio CRM197/Ps
CRM197-3,6A,7F	CRM197 / Ps 3 = 2.85	3.41
	CRM197 / Ps 6A = 3.15	3.77
	CRM197 / Ps 7F = 2.70	3.22
CRM197-5,9V,19F	CRM197 / Ps 5 = 3.20	3.82
	CRM197 / Ps 9V = 2.90	3.47
	CRM197 / Ps 19F = 3.47	4.15
CRM197-1,14,19A	CRM197 / Ps 1 = 2.87	3.43
	CRM197 / Ps 14 = 3.15	3.77
	CRM197 / Ps 19A = 3.45	4.13
CRM197- 22F,23F,33F	CRM197 / Ps 22F = 3.25	3.89
	CRM197 / Ps 23F = 2.80	3.35
	CRM197 / Ps 33F = 3.05	3.64
CRM197-4,6B,18C	CRM197 / Ps 4 = 2.90	3.47
	CRM197 / Ps 6B = 3.41	4.07
	CRM197 / Ps 18C = 3.10	3.71

In the exemplified molecular constructs, the Mean of the (w/w) Protein/type-specific Ps ratio is: 3.08 ± 0.24 (7.8%) corresponding to the Mean of the (mol/mol) ratio: 3.69 ± 0.29.

The above examples make evidence that different stoichiometries of synthesis, as addressed by the amount of reagents participating to the chemical equilibrium reported in the above chemical equation, may lead to a molecular construct of different

stoichiometry, where the amount of helper T-dependent carrier protein in the molecular construct can be optimally selected according to the optimal expression of immunogenicity of such molecular construct in the various age groups of the human population. In both, above exemplified, 15-valent formulations, containing five molecular constructs each carrying three type-specific Ps, the total amount of carrier protein CRM197 is ca. 5 µg, while the conjugated type-specific Ps are in the amount of ca. 1.0 and ca. 0.3 µg, respectively. Thus, at the dose of CRM197 equivalent to the one present in the *Prevnar* vaccine for each type-specific Ps conjugated, ca. 2 µg/dose, the total amount of CRM197 here exemplified in the 15-valent formulations would be ca. 10 µg or about 33% of the total amount present in the dose of the 13-valent *Prevnar* vaccine. Even in the hypothesis of a 23-valent formulation of a conjugate vaccine that would use the molecular model reported here, at comparable amount of protein/dose, the total amount of carrier protein would be significantly lower (ca. 50 %) of the amount present in the today's reported 13-valent or 15-valent vaccines formulated by association of separate, single type-specific, conjugate antigens. Accordingly, it is the purpose of the above reported embodiments to provide evidence of the fact that the disclosed multivalent antigenic molecular construct with built-in epitopes can be synthesized in a broad range of stoichiometric parameters in order to then

properly define, in mammalian hosts, the optimal dose of the construct even when considering the different age-groups to be immunized by a broad-spectrum vaccine formulation. It may be here important to recall that  
5 past clinical studies had demonstrated that, in adults and toddlers, the immune system could not discriminate, in terms of immunogenicity, among different sizes of the conjugated Ps to the protein carrier CRM197 as well as among multi-point (cross-linked) or mono-point (not  
10 cross-linked) models of conjugates (Eby R. et al., in : Modern Approaches to New Vaccines, CSH Ed., 119-123, 1994) even though such studies are not publically available for infants in the range 2-24 months of age.

EXAMPLE 7: Multivalent molecular construct with built-  
15 in epitopes based on the carrier protein Tetanus Toxoid  
In addition to the carrier protein CRM197, other well established helper T-dependent carrier proteins may be used in a polyvalent formulation which considers the molecular construct disclosed in this application. As  
20 an example, the Applicant has here considered Tetanus Toxoid (TT) as carrier protein, an universal immunogen safely used in paediatric immunization since many decades ago. In contrast to the carrier protein CRM197, TT has never been formulated in a 13 or 15-valent  
25 conjugate vaccine, so that the safety of such a potential high-dose protein vaccine in humans remains to be eventually established. Accordingly, the use of the disclosed multi-valent molecular construct for a protein like TT represents a rational approach for

limiting the amount of carrier protein in a 13 or 15-valent (or more) possible formulation based on such helper-T dependent carrier protein.

TT is a derivative of the homologous toxin, chemically treated for having the toxin purposely detoxified for a human use of the immunogen. The MW of the purified toxoid is quite comparable to that of the toxin, that is  $1.51 \times 10^5$ , encompassing 1,375 amino acids. However, among other features, the marked difference between toxoid and toxin resides in the amount of residual primary amino groups from the Lysine residues which remain in the toxoid structure after the chemical detoxification. An average of 50 reactive amino groups are about to be detected in the toxoid or about 50 % of those originally present in the structure of the toxin, which work as nucleophilic groups in the coupling reaction with the activated bacterial Ps. When comparing the structure of TT to that of CRM197 in terms of capability to compete in the coupling reaction as nucleophilic reagent, one may determine that TT has ca. 50 amino groups / mole (MW =  $1.51 \times 10^5$  for 1,375 aa) while CRM197 has 40 amino groups / mole (MW =  $58.5 \times 10^4$  for 535 aa), so that the molar density of them (which we define as "molar nucleophile activity") is 3.6 % in TT and 7.5% in CRM197, showing a much higher capability of the latter protein to serve as nucleophilic reagent in a given coupling reaction. However, given the significant difference in the MW of the two proteins (basically a factor = 2.6 in favor of TT) the molar

ratios of the protein carrier, for each of the carried carbohydrate antigens selected in the molecular constructs, may result advantageous for TT when one is willing to limit the amount of carrier protein / dose in a polyvalent formulation. In fact, at comparable weight dose of the two carrier proteins, TT results to be 2.6 times lower than CRM197 on molar basis. In contrast, attention must be paid to the fact that its MW may limit the possibility to obtain a molar ratio TT/type-specific Ps with a value  $\geq 1.0$  for the optimal induction of T-helper dependency in the host's immune system.

Here below, the Applicant reports on the physical-chemical features of such molecular construct using TT as carrier protein, synthesized according to the method above used for the CRM197-based molecular construct, with a stoichiometry in the reagents which allows the complete glycosylation of the carrier protein. Such a molecular construct can be considered as the basic component for a polyvalent formulation based on the TT carrier protein:

TABLE 10

Molecular construct	Average (w/w) ratio	Average molar ratio
	TT/Ps	TT/Ps
TT-6A,9V,23F	TT / Ps 6A = 2.08	0.96
	TT / Ps 9V = 1.90	0.90
	TT / Ps 23F = 2.15	1.00

In the case of multivalent conjugates of *N.meningitidis* Ps and *H.influenzae* Ps, as additional examples, here below is a comparison between the carrier proteins CRM197 and TT highlighting the relevance of the carrier protein in the different constructs (synthesized according to different stoichiometries as allowed by the general chemical equation above reported), as related to their MW in the definition of the molar ratio (protein/Ps), when considering for the protein and the Ps the MW values above reported in Tables 8-9:

TABLE 11

Molecular construct	Average (w/w) ratio	Average molar ratio
	TT/Ps or CRM/Ps	TT/Ps or CRM/Ps
TT-A,C,Hib	TT / PsA = 1.79	0.83
	TT / PsC = 2.05	0.95
	TT / PsHib = 1.91	0.89
CRM197-A,C,Hib	CRM197 / PsA = 2.18	2.60
	CRM197 / PsC = 1.87	2.24
	CRM197 / PsHib = 1.95	2.33
CRM197-A,C,W135,Y	CRM197 / PsA = 0.78	0.93
	CRM197 / PsC = 0.97	1.16
	CRM197 / PsW135 = 0.75	0.90
	CRM197 / PsY = 0.88	1.05

## BIBLIOGRAPHY

- Arndt and Porro, *Immunobiology of Proteins and Peptides*, Edited by M.Z. Atassi, Plenum Press, New York and London, pages 129-148, 1991.
- 5 - Berzofsky J.A. and Schechter A.N. *Mol. Immunol.*, 18: 751-763, 1981.
- Besnard J. et al., *Nature*, 492: 215-220, 2012.
- Bromuro, C., et al. (2010). *Vaccine* 28, 2615-2623.
- Calix J. J. et al. *J.Bacteriol.* 193:5271-5278, 2011.
- 10 - Dagan R. et al., *Vaccine* 28 (34): 5513-5523, 2010.
- Eby R. et al., *Modern Approaches to New Vaccines*, CSH Eds., 119-123, 1994.
- European patent EP 1868645.
- European patent EP 1501542.
- 15 - European Pharmacopoeia 5<sup>th</sup> Edition (2008).
- Giannini G. et al., *Nucl. Acid Res.*, 12, 4063-4069, 1984.
- Han, Y. et al. (2000). *Infect. Immun.* 68, 1649-1654.
- Kabat E.A., *J. Immunol.* 97: 1-11, 1966.
- 20 - Laemmli U.K., *Nature* 227, 680-685, 1970.
- Moreau M. et al., *Carbohydrate Res.*, 182(1):79-99, 1988.
- Nanra J.S. et al., *Human Vaccines and Immunotherapeutics*, 9:3, 480-487, 2013.
- 25 - O'Riordan K. and Lee J.C., *Clin. Microbiol. Rev.*, 17: 218-234, 2004.
- Porro M. et al., *J. Infect. Dis.*, 142 (5), 716-724, 1980.
- Porro M. et al., *Anal. Biochem.* 118: 301-306, 1981.
- 30 - Porro M. et al. *Medecine Tropicale*, 43: 129-132, 1983.

- Porro M. et al. *Molecular Immunology*, 22: 907-919, 1985.
- Porro M. et al. *Molecular Immunology*, 23: 385-391, 1986.
- 5 - Porro M. Edited by R. Bell and G. Torrigiani (WHO), pages 279-306; New York 1987.
- Pride M.W. et al., *Clin. And Vaccine Immunol.* 19 (8):1131-1141, 2012.
- Rebers P.A. and Heidelberger M., *J. Am. Chem. Soc.*, 10 83: 3056-3059, 1961.
- Reeves R.E. and Goebels W.F., *J. Biol. Chem.*, 139: 511-519, 1941.
- Richter S. et al., *Clin. Infect. Dis.*, 48:23-33, 2009.
- 15 - Rustici A. et al., *Science* 259: 361-365, 1993.
- Satzke C. et al., *J. Clin. Microbiol.*, 48(11): 4298, 2010.
- Schwebach, J. R., et al. 2002. *Infect Immun* 70:2566-2575.
- 20 - Swanson D., IDSA meeting, Boston, 2011.
- Towbin H. et al., *PNAS* 76: 4350-4354, 1979.
- Uchida T. et al., *J. Biol. Chem.* 248, 3838-3844, 1973.
- US Patent No. 4,711,779.
- 25 - US Patent No. 5,306,492.
- Xin, H. et al. (2008). *Proc. Natl. Acad. Sci. U.S.A.* 105, 13526-13531.
- Yao KH et al., *Diag. Microbiol. Infect. Dis.*, 70(3):291-8, 2011.
- 30 - Zucker D. and Murphy J.R., *Mol. Immunol.* 21, 785-793, 1984.

## CLAIMS

1. Antigenic multivalent molecular construct consisting of a basic unit comprising a helper-T dependent carrier protein covalently bound to a minimum of three carbohydrate structures of different serological specificity, wherein each carbohydrate structure comprises at least one of the repeating basic epitopes consisting of a minimum of five to twelve monosaccharide residues as assessed by molecular mass determination and NMR spectroscopy, said repeating basic epitopes being antigenically assessed by reactivity with type-specific or group-specific polyclonal or monoclonal antibodies through the determination of their respective MIC<sub>50</sub> values in the inhibition of their homologous Polysaccharide-Antibody reference system.

2. Antigenic multivalent molecular construct according to claim 1, wherein said carbohydrate structures are oligosaccharides or polysaccharides.

3. Antigenic multivalent molecular construct according to anyone of claims 1-2, wherein said repeating basic epitope consists of a minimum of eight to twelve monosaccharide residues.

4. Antigenic multivalent molecular construct according to anyone of the claims 1-3, wherein the helper-T dependent carrier protein is selected between the group of natural diphtheria mutants protein CRM197, diphtheria toxoid, tetanus toxoid, Protein D from *Haemophilus influenzae*, Pneumococcal surface proteins, Pneumococcal toxin, and their variants or derivatives,

such as tetanus toxoid chemically derivatized by adipic acid di-hydrazide spacer.

5. Antigenic multivalent molecular construct according to anyone of the preceding claims 1-4, wherein said  
5 carried carbohydrate antigens of different serological specificity are selected among those of *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Mycobacterium tuberculosis*, *Salmonella typhi*,  
10 *Escherichia coli*, *Vibrio cholerae*, *Candida albicans*, *Mycobacterium bovis* or a combination thereof.

6. Antigenic multivalent molecular construct according to claim 5, wherein the carried carbohydrate antigens are at least three capsular polysaccharides selected  
15 among type 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9N, 9V, 10A, 11A, 11B, 11C, 11F, 12F, 14, 15A, 15B, 15C, 17F, 18C, 19A, 19F, 20, 22F, 23A, 23F, 33F, 35B of *Streptococcus pneumoniae* and/or among polysaccharides of group A, C, W135 and Y of *Neisseria meningitidis* and/or  
20 polysaccharide of type b of *Haemophilus influenzae*, and/or K polysaccharide antigens of *Klebsiella pneumoniae* and/or polysaccharide antigens of *Staphylococcus aureus* and/or polysaccharide antigens of *Mycobacterium tuberculosis* and/or polysaccharide  
25 antigens of *Salmonella typhi* and/or polysaccharide antigens of *Escherichia coli* and/or polysaccharide antigens of *Vibrio cholerae* and/or polysaccharide antigens of *Candida albicans* and/or *Mycobacterium bovis*, or a combination thereof.

30 7. Antigenic multivalent molecular construct according to claim 6, wherein said construct comprises the carrier protein CRM197 and three capsular

- polysaccharides of *Streptococcus pneumoniae* selected among the triad of 3, 6A, 7F, 4, 5, 9V; 1, 6B, 14; 18C, 19A, 23F; 6C, 19F, 22F; 12F, 15B, 33F; 5, 9V, 19F; 1, 14, 19A; 22F, 23F, 33F; 4, 6B, 18C.
- 5 8. Antigenic multivalent molecular construct according to claim 6, wherein said construct comprises the carrier protein CRM197 and three capsular polysaccharides of *Streptococcus pneumoniae* selected among the triad of CRM197-3, 6A, 7F; CRM197-5, 9V, 19F;  
10 CRM197-1, 14, 19A; CRM197-22F, 23F, 33F; CRM197-4, 6B, 18C.
9. Antigenic multivalent molecular construct according to anyone of the preceding claims in monomeric or polymeric form.
10. Antigenic multivalent molecular construct according  
15 to anyone of the preceding claims for use in a vaccine for the protection of a subject from the infections due to pathogens selected from at least one infectious agent selected among *Streptococcus pneumoniae*,  
*Neisseria meningitidis*, *Haemophilus influenzae*,  
20 *Klebsiella pneumoniae*, *Staphylococcus aureus*,  
*Salmonella typhi*, *Escherichia coli*, *Vibrio cholerae*,  
*Mycobacterium tuberculosis*, *Mycobacterium bovis* and  
*Candida albicans*.
11. A vaccine formulation comprising at least one  
25 antigenic multivalent molecular construct as defined according to anyone of claims 1-9 in a physiologically acceptable vehicle, optionally together with an adjuvant or excipients pharmaceutically acceptable.
12. A vaccine formulation according to claim 11,  
30 wherein the dose of each type or group-specific carried carbohydrate antigen ranges between 0.1 to 10 µg, preferably being 1.0 µg.

13. A vaccine formulation according to claim 11 or 12, wherein said adjuvant is chosen between a mineral adjuvant selected from aluminium phosphate, aluminium hydroxide; an organic adjuvant selected from squalene-based adjuvants such as MF59, QF 21, Addavax and a biological adjuvant selected from monophosphoryl-lipid A and trehalose dicorynomycolate.
14. A vaccine formulation according to anyone of the claims 11-13, wherein the amount of adjuvant ranges between 0.1-1 mg/dose, preferably being 0.5 mg/dose.
15. A vaccine formulation according to anyone of the claim 11-14, said formulation being suitable for the administration by subcutaneous, intramuscular, intracutaneous or transcutaneous route.
16. A broad-spectrum polyvalent vaccine formulation according to anyone of the preceding claims 11-15, for use in medical human or veterinary field for the protection of a subject from the infections due to bacterial pathogens selected from at least one infectious agent selected among *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *M. tuberculosis*, *Salmonella typhi*, *Escherichia coli*, *Vibrio cholerae*, *C. albicans* and *M. bovis*, or a combination thereof.
17. A broad-spectrum polyvalent vaccine formulation according to claim 16, wherein said subject belongs to the paediatric population.
18. A broad-spectrum polyvalent vaccine formulation according to claim 16-17, for the prevention of Invasive Pneumococcal Diseases due to *Streptococcus pneumoniae*, comprising one or more antigenic

multivalent molecular constructs selected among CRM197-3, 6A, 7F; CRM197-4, 5, 9V; CRM197-1, 6B, 14; CRM197-18C, 19A, 23F; CRM197-6C, 19F, 22F; CRM197-12F, 15B, 33F or among CRM197-3, 6A, 7F; CRM197-5, 9V, 19F; CRM197-1, 14, 19A; 5 CRM197-22F, 23F, 33F; CRM197-4, 6B, 18C.

19. A broad spectrum vaccine formulation according to claims 16-17, for the prevention of the infections due to *Neisseria meningitidis* comprising an antigenic multivalent molecular construct containing the group-specific carbohydrate structures A, C, W135 and Y. 10

20. A broad spectrum vaccine formulation according to claims 16-19, for the prevention of the systemic and pulmonary infections due to more than one infectious agent selected between/among *Streptococcus pneumoniae*, 15 *Neisseria meningitidis*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *M. tuberculosis*, comprising more than one antigenic multivalent molecular construct containing said agent-specific carbohydrate structures.

20 21. A broad spectrum vaccine formulation according to claims 16-19, for the prevention of the intestinal infections due to more than one infectious agent selected between/among *Salmonella typhi*, *Escherichia coli*, and *Vibrio cholerae*, comprising more than one 25 antigenic multivalent molecular construct containing said agent-specific carbohydrate structures.

22. A broad spectrum vaccine formulation according to claims 16-19, for the prevention of the systemic and genitourinary infections due to *Candida albicans* and 30 *Escherichia Coli* comprising more than one antigenic multivalent molecular construct containing said agent-specific carbohydrate structures.

23. Vaccine formulation according to any one of claims 11-22 for the separate, simultaneous or sequential administration with an Endotoxoid of gram negative bacteria, said Endotoxoid being selected in the group  
5 consisting of Endotoxoid of *N. meningitidis* Group B, *E. coli*, *S. typhi*, *V. cholerae*, *S. enteritidis*, *B. pertussis*.

24. A conjugation process for preparing the antigenic multivalent molecular construct according to anyone of  
10 claims 1-9, which comprises the following steps:

a) chemical activation of the at least three antigenically different carbohydrate structures to mono-functionality or polyfunctionality by O-dehydrogen uncoupling via oxidation and reductive  
15 amination forming imine reduced bonds with an alkyl diamine spacer, then derivatized to active esters;

b) simultaneous coupling, or a step-by-step coupling, of the at least three ester-derivative carbohydrate structures to the amino groups of the polyfunctional  
20 carrier protein through the formation of amide bonds.

25. A conjugation process according to claim 24, wherein the carbohydrate structures are chemically activated in their corresponding diamine butyric acid derivatives and the active esters are succinimidyl  
25 esters.

26. A conjugation process according to anyone of the claims 24-25 wherein said polyfunctional carrier protein is CRM197.

27. A conjugation process according to anyone of the  
30 claim 23-26, wherein said at least three carbohydrate structures are selected among the following triads of polysaccharides from *Streptococcus pneumoniae* 3, 6A, 7F;

4, 5, 9V; 1, 6B, 14; 18C, 19A, 23F; 6C, 19F, 22F; 12F, 15B, 33F;  
5, 9V, 19F; 1, 14, 19A; 22F, 23F, 33F; 4, 6B, 18C.

28. A conjugation process for preparing the antigenic multivalent molecular construct according to anyone of  
5 claims 1-9, which comprises the simultaneous coupling or the step-by-step coupling of the amino groups of the polyfunctional carrier protein with at least three antigenically different carbohydrate structures, via reductive amination forming imine-reduced bonds, such  
10 carbohydrate structures being previously activated to monofunctionality or polyfunctionality, with or without spacers, by O-de-hydrogen uncoupling via oxidation.

29. Antigenic multivalent molecular construct obtainable through the conjugation process according to  
15 anyone of the claims 24-28.

20

25

30

1/13

<sup>1</sup>H-NMR spectrum of Ps 3 and Ps3-DAB derivative




FIG.1




FIG.2

2/13




FIG.3

<sup>1</sup>H-NMR spectrum of Ps6A and Ps6A-DAB derivative




FIG.4

3/13




FIG.5




FIG.6

4/13

<sup>1</sup>H-NMR spectrum of Ps7F and Ps7F-DAB derivative




FIG.7




FIG.8

5/13




FIG.9

6/13

FIG.10





FIG.11



7/13





FIG.12

8/13



FILE	1.	METHOD	0.	RUN	3	INDEX	3	BIN	3
PEAK#		AREA%		RT		AREA	BC		
1		7.2		7.05		43170	01		
2		8.12		10.98		48686	02		
3		84.68		11.64		507727	03		
TOTAL		100.				599583			

FIG.13

9/13

FIG.14





FIG.15

10/13







FIG.16



	CRM197	CRM-3,6A,7F
LogEC50	1.084	1.008
EC50	12.14	10.19

FIG.17



	3-DAB	CRM-3,6A,7F
LogEC50	-1.937	-2.187
EC50	0.01156	0.006506

12/13





FIG.20



	6A-DAB	CRM-3,6A,7F
LogEC50	-0.2957	-0.2820
EC50	0.5061	0.5224

FIG.21

13/13





FIG.22



	7F-DAB	CRM-3,6A,7F
LogEC50	0.3390	0.3023
EC50	2.183	2.006

FIG.23

**INTERNATIONAL SEARCH REPORT**

International application No  
PCT/EP2014/051670

**A. CLASSIFICATION OF SUBJECT MATTER**  
 INV. A61K39/095 A61K39/09  
 ADD.  
 According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
 Minimum documentation searched (classification system followed by classification symbols)  
 A61K  
 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EPO-Internal, BIOSIS, CHEM ABS Data, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PORRO M ET AL: "A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 23, no. 4, 1 April 1986 (1986-04-01), pages 385-391, XP023682553, ISSN: 0161-5890, DOI: 10.1016/0161-5890(86)90136-7 [retrieved on 1986-04-01] page 386 page 390, right-hand column, paragraph 3	1-29
A	EP 1 501 542 B1 (BIOSYNTH SRL [IT]) 22 August 2007 (2007-08-22) cited in the application claim 1	1-29

Further documents are listed in the continuation of Box C.  See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search <b>19 May 2014</b>	Date of mailing of the international search report <b>04/06/2014</b>
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <b>Mata Vicente, Teresa</b>
--	---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2014/051670
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1501542	B1	22-08-2007	AT 370745 T 15-09-2007
			AU 2002309259 A1 11-11-2003
			AU 2003242535 A1 11-11-2003
			CA 2484279 A1 20-11-2003
			DE 60315827 T2 15-05-2008
			EP 1501542 A1 02-02-2005
			ES 2293002 T3 16-03-2008
			US 2006165730 A1 27-07-2006
			WO 03094959 A1 20-11-2003
			WO 03094961 A1 20-11-2003